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1. AIMS
The aims of this research were:
1. To find the optimal incubation time and to obtain the association curve
where benzodiazepine receptor and flunitrazepam reach
equilibrium and to determine the stability period of receptor/ligand 
equilibrium.
2. To determine the location of the highest densities of benzodiazepine 
receptors in human brain tissue.
3. To study the effects of factors such as age, sex, causes of death and post­
mortem conditions (delay-time interval between death and autopsy) 
which might affect the receptor molecules.
4. To study the effect of benzodiazepine drugs on benzodiazepine receptor 
densities.
5. To develop a single solid-phase extraction method for the determination 
of benzodiazepine drugs in human post-mortem whole blood.
6. To develop a single solid-phase extraction method for the determination 
of benzodiazepine drugs in human post-mortem brain tissue.
7. To compare solid-phase extraction methods with conventional solvent 
extraction methods.
-2 -
8. To compare and correlate the concentrations of benzodiazepine drugs in 
human post-mortem blood samples from different sites (jugular vein, 
axillary vein, femoral vein and heart).
9. To compare and correlate the concentrations of benzodiazepine drugs in 
human post-mortem blood samples to their concentrations in brain 
tissue.
-3 -
2. SUMMARY
A brief introduction is given to benzodiazepine drugs and 
benzodiazepine receptors, particularly in human brain tissue.
Human post-mortem brain tissue samples and their authentic blood 
samples were collected at the City Mortuary, Glasgow.
Benzodiazepine receptor binding sites were studied in human brain 
tissue samples. The study revealed that the incubation period for 
maximum benzodiazepine binding was between 30 and 60 minutes. The 
maximum regional distribution of benzodiazepine receptors was 
investigated and the highest densities of bound drug receptors were found 
to be in the frontal cortex area. Intermediate densities were found in most 
other areas (post-central, occipital and hippocampus) and the lowest 
densities were found in the cerebellum cortex and temporal cortex. No 
significant statistical variations in concentrations of receptor binding sites 
were found with age or sex. A considerable drop in the binding site 
concentration in subjects who died from a variety of causes of death was 
found only where they were shown to have been treatd with 
benzodiazepine drugs prior to death.
Methods for extraction and analysis of benzodiazepine drugs were 
investigated. The developed methods were quick, easy and reproducible.
A solid-phase extraction procedure was developed to detect, identify 
and quantify the benzodiazepine drugs (triazolam, temazepam, desmethyl-
-4 -
diazepam and diazepam) in whole post-mortem blood samples using High
Pressure Liquid Chromatography. The extraction was performed by
elation of the drugs with chloroform from buffered blood adsorbed on 
Bond Elut Cg columns. The separation time for the five chosen drugs was
less than 14 minutes on HPLC operated at a flow rate 1 ml/minute. From 
a total of 1 ml of post-mortem blood, the lower detection limit was 50 
ng/ml for all the drugs investigated. The relative recoveries were 
101+3% for triazolam, 88 + 3.5% for temazepam, 86 + 2% for 
desmethyldiazepam and 93 + 4% for diazepam at that level.
Comparison of the extraction efficiency of the developed method 
(solid-phase extraction) with liquid-liquid extraction method was carried 
out for human post-mortem blood samples results. The solid phase 
method was found to be more efficient than liquid-liquid extraction.
Having established the highest densities of benzodiazepine receptor
sites in human brain tissue, the concentration of benzodiazepine drugs in
human brain tissue samples was determined by HPLC. The levels found
were compared to the levels found in human post-mortem blood samples
taken from the same subjects. For this purpose a solid-phase extraction
procedure for human brain tissue was developed. It can be used to detect,
identify and quantify benzodiazepine drugs in human brain tissue samples
using HPLC. The drugs were eluted with chloroform from buffered brain 
tissue (one gram) adsorbed on Bond Elut Cg columns. As before, the
separation time was less than 14 minutes on the HPLC system operated at 
flow rate 1 ml/minute. From a total of one gram of human brain (pre­
central cortex tissue) the lower detection limit was 10 ng/gram for all the
-5 -
drugs investigated. The relative recoveries were 101 ± 2.9% for triazolam, 
84 + 7% for temazepam, 95 + 8% for desmethyldiazepam and 95 + 7.5% for 
diazepam. Higher benzodiazepine concentrations were obtained from blood 
compared to brain samples.
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3. BENZODIAZEPINES - LITERATURE REVIEW
3.1 INTRODUCTION
The first benzodiazepines were synthesized in the 1930s but were not 
systematically evaluated until 20 years later. The prototype, chlordiazepoxide, 
tamed animals and had muscle relaxant and sedative properties. Given to 
chronic schizophrenic patients, it alleviated their anxiety without altering their 
psychotic features. Chlordiazepoxide was extensively evaluated in anxious 
patients and marketed in 1960 (Lader Malcolm, 1983). Diazepam was 
marketed 3 years later. Since that time a large number of benzodiazepines 
have been synthesized and tested for activity, and more than 20 have been 
introduced into clinical use.
One of the most fascinating phenomena related to the benzodiazepines 
has been the rapid acceptance of these drugs by clinicians and by patients. 
Only 16 years after the introduction of the prototype, chlordiazepoxide or 
only 13 years after the introduction of diazepam, the latter was itself ranked 
second amongst the most prescribed drugs in England, only surpassed by 
paracetamol (Blaha & Bruckmann, 1983). Six benzodiazepines accounted for 
7% of all prescriptions in England in 1976 (Blaha & Bruckmann, 1983). Similar 
data have been reported for many other western countries (Blaha & 
Bruckmann, 1983; Muller-Oerlinghausen, 1986). Estimates prepared for 
several European countries suggest that between 10 and 20% of the adult 
population take a benzodiazepine drug at least once a year, with quite 
impressive differences between some of the countries (Lader, 1978,
- 7 -
Bellantuono et al., 1980; Blaha & Bruckman, 1983; Muller Oerlinghausen, 
1986). It seems highly unlikely that any use of drugs to such an extent would 
be justified medically. Accordingly, several authors have expressed major 
concerns about what they call a medical misuse of benzodiazepines (Nolan & 
O'malley, 1988; Lader, 1978; Tyrer, 1984; Catalan & Gath, 1985). The concern 
about the obvious misuse of benzodiazepines has been greatly enhanced by 
the realization during the last few years that problems of drug dependence 
occur more frequently than had been thought for the many years of clinical use 
of these drugs (Schoff, 1983; Tyrer et al., 1983; Ashton, 1984; Tyrer, 1984; 
Catalan & Gath, 1985).
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3.2 INDICATIONS
It is obvious that rapid acceptance by the medical profession would not 
have taken place if the benzodiazepines were not highly active and also 
relatively safe. They are used today for a broad spectrum of therapeutic 
indications: (Table 1) (Shader & Greenblatt, 1981; Shader, 1981; Gilman et al., 1985; 
Gilman et al., 1990; Lader, 1989; Livingston, 1991,; Katzung, 1987; Gillies, 1986).
1. Anxiolytic
Although such hypnosedatives as meprobamate and the barbiturates 
are powerful agents, they are effective only in doses which produce 
drowsiness and impairment of mental and physical performance. The 
benzodiazepines exert a more specific effect on the limbic system, and can 
therefore reduce anxiety in doses which do not produce somnolence. 
Nevertheless, large doses are sedative and one of their main uses is as 
hypnotics.
2. Anticonvulsant
Benzodiazepines raise the threshold for electrically induced fits and 
those due to Leptazol or local anaesthetic in experimental animals. In clinical 
practice diazepam, clonazepam, lorazepam and nitrazepam are effective in 
several forms of epilepsy.
- 9 -
3. Muscle Relaxant
Decreased voluntary muscle tone occurs in normal individuals and in 
patients with spasticity. In therapeutic doses, neuromuscular transmission is 
not affected but there is inhibition of polysynaptic reflexes within the spinal 
cord. This muscle relaxation is due to facilitation of inhibitory GABA 
receptors in the cord. Although this action may be beneficial in spasticity and 
muscle spasm due to pain, post-anaesthetic respiratory depression can be 
prolonged in patients given curare and a benzodiazepines.
-10-
Table 1: The Most Prescribed Benzodiazapines.
Drug Daily dose 
mg.
Time half -life 
Parent compound 
0 0
Indications
Short acting
Triazolam tb. 0.125-0.25 2 -4 Hypnotiic
Midazolam i.v 2.5 - 7.5 2 Psychosedation
Lormetazepam 0.5-1 10 Hypnotic
Intermediate acting
Temazepam 5-60 5-20 Hypnotic
Oxazepam tb. 30 -180 5-20 Anxiety
Lorazepam tb. 3-10,i.v & i.m 1 -4 10-20 Anxiety,
premedication
anticonvulsant
Long acting
Diazepam tb. 6 - 40, i.v 5-30 20-50 Anxiety, hypnotic, 
muscle relaxant, 
anaesthesia.
Clonazepam tb. 4 -8,  i.v 1 30 Anticonvulsant
Chlordiazepoxide 10-25 30 Hypnotic,
premedication
Nitrazepam tb., cap., 2.5 -10 24 Hypnotic
Prazepam tb. 10 - 60 40-100 Anxiety
-11-
3.3 MECHANISM OF ACTION
Since an exact knowledge about the mechanism of action is one of the 
fundamentals of rational drug therapy, especially if the drugs are as frequently 
used as the benzodiazepines, to know how benzodiazepines act is important 
even for their therapeutic use. Moreover, the search for the molecular 
mechanism of action of the benzodiazepines was always motivated by the 
hope of finding a key for a better understanding of the biological basis of 
action.
The mechanism of action of benzodiazepines was not known until 1977, 
when Mohler and Okado and Squires and Braestrup described the 
characteristics of a benzodiazepine binding site in the rat brain, known as a 
benzodiazepine receptor. Shortly after it was recognized that these sites are 
present in high densities in some regions of the human brain (Braestrup et al, 
1977). The benzodiazepine receptor have been intensively studied in 
laboratory animals and have been characterized in terms of their 
pharmacology, physiology, anatomy, immunology and biochemistry (Mohler 
et al., 1986).
Much less is known about this receptor in the human brain (Zezula et 
al., 1988). Biochemical assays have demonstrated the presence of 
benzodiazepine receptors in human brain with pharmacological and molecular 
properties very similar to those described in the rat brain (Braestrup et al., 
1977, Mohler & Okado, 1978, Richards et al., 1986, Speth et al., 1978)
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3.4 PHARMACOKINETICS
The pharmacokinetics of benzodiazepines (Figures 1,2,3) are described 
in detail in several recent reviews (Klotz, 1983, Greenblatt et al., 1981, 
Greenblatt et al., 1983, Laurence and Bennett, 1987, Levine and Clark, 1983, 
Lewis, 1980, Modell, 1984). The various benzodiazepines (Table 1) can be 
classified according to their plasma half lives as short, intermediate and long- 
lived drugs.
Four routes of metabolism - dealkylation, oxidation, reduction, and 
glucuronidation - account for the principal metabolic pathways of various 
benzodiazepines. Several routes may be employed with some compounds, 
producing a succession of active metabolites. Chlordiazepoxide, for instance, 
undergoes first dealkylation, then oxidation and then reduction to form a 
common metabolite of many of these agents, N-desmethyldiazepam 
(nordiazepam).
Some drugs on the market are essentially pro-drugs of nordiazepam, 
very quickly being converted from parent compound to that active metabolite. 
This may occur either by dealkylation (prazepam) or by hydrolysis 
(Clorazepate dipotassium). Drugs that have a hydroxy group at the 3-position, 
such as oxazepam and lorazepam, form no active metabolites but are directly 
conjugated.
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Figure 1 Biotransformation of Triazolam.
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Figure 2 Bio transformation of Diazepam.
I-DESMETHYLDIAZEPAM OXAZEPAM
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Figure 3 Bio transformation of Benzodiazpines.
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3.5 ABUSE OF BENZODIAZEPINES
The first report about the abusers of benzodiazepines stated that up to 
40% of narcotic abusers were ’diazepam users’ (Woody et alv 1975). Many 
studies were carried out later indicated that most, if not all, of the 
benzodiazepines that are readily available, are abused (Marks, 1978, updated 
in 1983, Marks, 1983a, b). Benzodiazepines are the UK's most prescribed 
drugs. They are mainly prescribed as tranquillisers for anxiety problems but 
also as hypnotics for insomnia. Combined with other medicines, 
benzodiazepines are also used to treat a host of physical conditions in which 
anxiety and emotions are thought to play a part (The Institute for the Study of 
Drug Dependence, 1991).
Most benzodiazepine prescriptions are long term repeat prescriptions 
(Cooper, 1987). In 1988 the Committee on the Safety of Medicines 
recommended that benzodiazepines be prescribed only in the lowest possible 
doses for up to four weeks (I.S.D.D., 1987). It has been estimated that a quarter 
of UK adults take benzodiazepines at sometime during a year (Ashton et al., 
1989) and that 3% - 1.2 million people - take hypnotics or sedatives (around 
90% of these are benzodiazepines (Cooper, J., 1987) throughout the year. The 
proportion of women taking benzodiazepines long term (4%) is twice that for 
men (Ashton et al., 1989). It is widely held that much benzodiazepine 
prescribing is unjustified, inappropriate and, if prolonged, ineffective for the 
treatment of anxiety.
Growing awareness among GPs of the limitations and risks of 
benzodiazepines has resulted in a fall in the number of prescriptions in Great
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Britain every year since 1979, from just over 30 million to just over 18.5 million 
in 1990 (Personal Communication from Department of Health, 1991).
Navaratnam, 1982, found that 22 out of 57 countries indicated the 
existence of some benzodiazepine abuse, but of these only 16 suggested that 
there was a problem causing public health concern. The abuse involved 22 
different benzodiazepines (if illicit traffic is taken as an indication of abuse). 
The data tends to indicate that benzodiazepine abuse is minor compared to the 
general drug abuse problem or even opiate abuse. Several countries stressed 
that benzodiazepine abuse was a secondary component to the problems 
associated with narcotic drugs.
It has been known that alcoholics are users of sedative compounds for 
some time now (previously barbiturates - Devenyi and Wilson, 1971). 
However, the extent of benzodiazepine use along with alcohol abuse has only 
recently been quantified (Busto et al., 1983a). Alcoholics are normally 
unreliable witnesses (Devenyi and Wilson, 1971, Orrego et al., 1979 ) as are 
narcotic abusers (Dally, 1983).
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3.6. BENZODIAZEPINES AND THE LAW
The majority of countries, both industrially developed and those of the 
Third World, now have laws which cover control of benzodiazepine use in 
clinical medicine. The regulations usually restrict availability to prescription, 
either not repeatable; limited in the number of repeats; or limited as to the 
period over which repeats may be dispensed by pharmacists (Marks, 1985). In 
the United Kingdom benzodiazepines are prescription only medicines and are 
controlled under Class C of the Misuse of Drugs Act, 1971 (Japp et al., 1988).
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3.7 CONCLUSIONS
No data are available concerning benzodiazepine receptor and clinical 
effects in man and since we know from clinical experience that ataxia and 
muscle relaxation are usually seen only after high doses of benzodiazepines, it 
might be speculated that similar, but certainly not identical correlations exist 
between receptor occupancy and clinical effects or side effects in man.
It has now become possible to study the receptors occupancy in the 
human brain, which is the critical determinant for biological response. This 
will help to determine to what extent blood level measurements are a 
predictor for receptor occupancy in the brain.
Only a few workers have dealt directly with the development of reliable 
methods for the routine screening and subsequent confirmatory and 
quantitative analysis for benzodiazepines in whole post-mortem blood and 
human brain tissue (pre-cortex area, frontal lobe) samples.
The objective of this study was to deal directly with the development of 
reliable methods for the routine screening and subsequent confirmatory and 
quantitative analysis for benzodiazepines in whole blood and human brain 
tissue (pre-cortex area) samples.
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3.8 BENZODIAZEPINE RECEPTORS IN HUMAN BRAIN
3.8.1 RECEPTOR COMPONENTS
Receptors may be defined as macromolecules to which a hormone, 
neurotransmitter, or neuromodulator attaches. Receptors are located either in 
association with the plasma membrane, such as those for neurotransmitters 
and some hormones, or with cytoplasmic or nuclear compartments, such as 
steroid hormone and T3 receptors, respectively. Receptor activation regulates 
a variety of cellular activities, including the degree of ion permeability, 
enzyme activity, or the rate or type of transcription and translation. Thus, 
receptors may be viewed as the primary site for regulating cellular activity in 
all organs and tissues.
Neurotransmitter receptor proteins are synthesized in the neuron, 
transported in small vesicles and inserted into the plasma membrane. 
Eventually the receptors are returned to the cytosol by endocytosis and 
destroyed by lysosomal enzymes. A common end point for neurotransmitter 
receptor function is a change in membrane permeability to ions. The basic 
units of a receptor are the transmitter recognition site and an ion channel. It is 
unclear whether the recognition site and ion channel are parts of the same 
molecule, or are separate constituents of a supramolecular complex. Evidence 
suggests that ion channels may be associated with more than one type of 
recognition site. There are at least two ways in which recognition site 
activation leads to channel opening. One is through a direct coupling between
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the recognition site and the ion channel, and the other by way of a cyclic 
nucleotide system.
It also appears that there are membrane constituents that can regulate 
recognition site number and affinity. These phospholipid or protein modulators 
are capable of rapidly altering the availability of receptors for neurotransmitters. 
Because receptors are composed of a number of interacting units, there are a 
number of ways in which they can be modified (Enna, 1983, Ganong, 1981, 
Devlin, 1986).
3.8.2 BENZODIAZEPINE RECEPTORS
In 1977 two groups reported specific, high affinity receptors for 
benzodiazepines (Braestrup and Squires, 1977; Mohler and Okada, 1977). 
These receptors definitely have been shown to be functionally linked to GABA 
receptors. GABA and its analogues enhance the binding of benzodiazepines to 
their receptors (Tallman et al., 1978; Supavilai and Karobath, 1980), and 
benzodiazepines enhance GABA activation of chloride channels (Gallager, 
1978; Study and Barker, 1981). Under certain conditions it also appears that 
benzodiazepines may be able to enhance GABA receptor binding (Guidotti et 
al., 1978; Skerritt et al., 1982). Benzodiazepine binding is also enhanced by 
chloride ion (Costa et al., 1979), and both GABA and benzodiazepine agonists 
are able to protect the receptors for other classes of compounds against heat 
inactivation (Gavish and Snyder, 1980).
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Several compounds have been found to interact with the 
benzodiazepine receptors in quite interesting ways. The benzodiazepine Ro 
15-1788 appears to antagonize the pharmacological effects of the classical 
benzodiazepines, such as diazepam, being able to reverse their anticonvulsant, 
sedative, and ataxic effects (Hunkeler et al., 1981). The compound CGS 8216 
appears to behave in a very similar manner (Czrink et al., 1982). Another 
group of compounds, the beta-carboline-3-carboxylate esters, not only 
antagonize several effects of benzodiazepines, but can act as convulsants or 
preconvulsants on their own (Oakley and Jones, 1980; Cowen et al., 1981; 
Braestrup et al., 1982). Actions of these (inverse agonists) can also be blocked 
by the (antagonists) such as Ro 15-1788 (Ploc et al., 1982). It has also been 
found that GABA, which enhances the binding of benzodiazepine agonists, 
decreases the binding of the inverse agonists to the benzodiazepine receptor 
(Braestrup and Neilsen, 1981).
The interactions of some of these compounds with the benzodiazepine 
receptor have revealed that at least two subtypes of this binding site exist in 
brain. Specifically, the triazolopyridazine anxiolytics, CL218,872, and some 
beta-carboline-3-carboxylate esters inhibit benzodiazepine binding in a 
biphasic manner (Klepner et al., 1979; Neilsen and Braestrup, 1980). Both 
types of ligand bind with greater affinity to the receptor subtype that 
predominates in the cerebellum, termed (Type 1 or benzodiazepine 1). Certain 
benzodiazepine agonists also bind preferentially to the type 1 receptor 
subtype, which appears to correspond to distinct peptide on SDS gels (Sieghart 
et al., 1983). The two subpopulations differing in affinity for 
triazolopyridazines also appear to be two different proteins on the basis of 
ontogeny, regional localization (Young et al., 1981) detergent solubilization
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properties, and sensitivity to modulation by ions. When investigated by
radioligand, the betacarbolines directly demonstrate biphasic dissociation 
curves in those brain regions which show both Bzj, and Bz2 receptors, such as
the hippocampus and the cerebral cortex (Gee et al., 1983). GABA was found 
to enhance the affinity of benzodiazepine agonist binding to the Bzl receptor 
of the cerebellum and cortex as well as the Bz2 receptors of the hippocampus 
and cortex, while the Bzl receptors in the hippocampus were apparently less 
affected (Gee et al., 1983). Several workers (Gee et al., 1983, Braestrup et al., 
1982) interpret the apparent heterogeneity of benzodiazepine receptors on the 
basis of different allosteric states of a single receptor protein, modulated by 
ligands differing in efficacy.
Insights into the molecular nature of the benzodiazepine receptors have 
been provided by the ability of certain benzodiazepines to be used as specific, 
irreversible photoaffinity labels of the receptor. Benzodiazepines with a nitro 
group in the 7 position of the conjugated ring, such as flunitrazepam and 
clonazepam (Mohler et al., 1980; Sieghart and Mohler, 1982), are chemically 
activated by ultraviolet light and bind covalently to the receptor (Sherman- 
Gold, 1983). When maximal amounts of pH] flunitrazepam are incorporated 
into membrane-bound benzodiazepine receptors in this way, about 25% of the 
total number of receptors present are labelled with tritium (Mohler et al., 1980 
Karobath and Supavilai, 1982). The remaining receptors cannot be detected 
upon assay of the membranes with labelled benzodiazepine agonists 
(nonradioactive flunitrazepam being used for photoaffinity labelling). If, 
however, labelled Rol5 1788, CGS 8216, or a beta-carboline is used to assay the 
membranes, the receptors can still be detected and show unaltered affinity 
and a decrease of only 25% or less in numbers (Hirsch, 1982; Thomas and
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Tallman 1983). Benzodiazepine agonists are able to displace radioactive beta- 
carboline binding to photoaffinity-labelled membranes, but with greatly 
reduced affinity compared to their effects in control membranes. Thus it 
appears that the benzodiazepine agonist interacts with these receptors in a 
way that involves a functional complex of several binding sites, with the 
photolabelling of one site leading to a decreased affinity for agonists in three 
more sites. The antagonists or inverse agonists do not seem to invoke such 
receptor interactions. Indeed, when an antagonist is used for photolabelling, 
more than 90% of the sites could be labelled, and sites not labelled had 
unaltered affinities for both agonists and antagonists (Mohler et al., 1984a). A 
further interesting interaction is that the 25% covalent incorporation 75% loss 
of affinity is not seen in detergent - solubilized extracts, where greater than 
50% of the available sites are covalently photolabelled with pH] flunitrazepam 
(Thomas and Tallman, 1981).
The assignment of different benzodiazepine actions to receptor 
subtypes is further undetermined by the introduction of imidazopyridines, 
zolpidem and alpidem. Zolpidem shows a seventy-fold selectivity for type I 
receptors, but is hypnotic. Alpidem is a non-sedative anxiolytic with high 
affinity for both type I central receptors and the 'peripheral type' receptors 
(Langer et al., 1990). It would seem that there is some evidence for bz receptor 
multiplicity. The selectivities of ligands for the proposed subtypes are, 
however, not very high. Furthermore, different benzodiazepine ligands seem 
to have subtly different selectivities for different variants of the subunits of the 
GABA receptor complex (Luddens and Wisden, 1991). It may be that subunit 
composition is responsible for the benzodiazepine receptor for the
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benzodiazepine receptor subtypes, and that the situation is far more complex 
than that outlined above.
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3.8.3 ALTERATION OF BENZODIAZEPINE RECEPTORS IN MATS!
IN PATHOLOGICAL CONDITIONS
Because of the clinical efficacy of benzodiazepines and GABA-mimetics, 
it has been postulated that an alteration of one or more components of the 
benzodiazepine/GABA receptor complex may occur in some of the disease 
states where these drugs are of therapeutic value. Consequently, an 
understanding of these receptor changes in the central nervous system (CNS) 
might provide mechanistic insight into the disease process and lead to more 
effective therapeutic interventions. Several approaches have been taken to test 
whether alteration in benzodiazepine or GABA binding are affected in clinical 
entities. One approach attempts to measure the binding of different ligands to 
these receptors in animal models of disease. A second approach is to perform 
similar binding studies in human tissue obtained either post-mortem or 
through surgical resection. In both animal and human studies, receptor 
binding can be assayed either in homogenates of tissue obtained form different 
brain regions, or by quantitative autoradiographic techniques. A third 
approach, is the direct and noninvasive measurement of in vivo receptor 
binding characteristics in the patient using appropriately labelled ligands and 
currently available imaging techniques, such as a positron emission 
tomography (Phelps and Mazzoiotta, 1985).
Using one or more of these approaches, altered benzodiazepine and/or 
GABA receptor properties have been sought in a number of clinical disorders 
which include Huntington's disease, various types of epilepsy, Alzheimer’s
disease, alcoholism, Parkinson’s disease and others. Table 2 shows the 
changes in the density of benzodiazepine receptor (B^x) in post-mortem brain
samples of patients suffering from different mental disorders (Muller, 1987).
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Table 2: Changes in the density of the Benzodiazepine receptor 
(Bmax) i*1 post-mortem brain samples of patients suffering 
from different mental disorders (From Walter Muller, 1987).
D ise a se Br a in  Re g io n % Ch a n g e  of  
Bm a x
Depression Frontal Cortex ±0
Hippocampus ±0
Frontal Cortex ±19
Temporal Region ±0
Lesch-Nyhan Occipital Cortex ±0
Syndrome Temporal Cortex ±0
Frontal Cortex ±0
Parietal Cortex ±0
Alcoholism Frontal Cortex ±0
Schizophrenia Frontal Cortex ±0
Senile Dementia 
Alzheimer Type
Temporal Cortex ±13
3.8.4 GAMMA-AMINOBUTYRIC ACID RECEPTORS
GABA represents the most important inhibitory neurotransmitter. By 
using a simple chromatographic technique in 1949, Gamma-Aminobutyric 
Add (GABA) was first isolated from mammalian central nervous systems. For 
the past twenty years few have doubted its importance as a major inhibitory 
neurotransmitter in the mammalian central nervous system (Roberts, 1984). 
All brain regions contain GABA, particularly abundant in the substantia nigra, 
globus pallidus and hypothalamus (Iversen and Bloom, 1972, Ottersen and 
Storm-Mathison, 1984). GABA is localized in nerve terminals (Neal and 
Iverson,, 1969) from which it can be released by depolarizing stimuli in a 
caldum dependent manner (Bradford, 1970). The majority of these sites 
involve release from intemeurons, though there are some long projection 
pathways which use this transmitter, such as the cerebellar output neuron, the 
Purkinje cell (ten Brugencate and Engberg, 1969), the striatonigral pathway 
(Precht and Yoshida, 1971; Nagai et al 1978) and the nigrotectal pathway 
(Garcia-Munoz et al 1977) (for reviews see Snodgrass 1983, Roberts, 1984, and 
Martin, 1990).
Most of the GABA in the central nervous system is derived from 
glutamic acid through a reaction catalysed by glutamic acid decarboxylase 
(GAD). Like other neurotransmitters GABA is stored in nerve terminals and is 
released by a caldum dependent process following depolarization (Ryan and 
Roskoski, 1975). The liberated GABA is re-accumulated by a sodium- 
dependent, high affinity uptake system located on nerve terminals and glia 
(Iversen and Neal, 1968). Some GABA is metabolized to sucdnic 
semialdehyde by GABA transaminase (GABA-T). The functional significance
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of these biochemical events is indicated by the fact that agents which inhibit 
GAD significantly reduce brain GABA levels and decrease the seizure 
threshold (Swaya et al, 1978). Conversely, drugs which inhibit GABA-T 
increase the GABA content, depress central nervous system activity, and raise 
the seizure threshold (Meldrum, 1978). Likewise, drugs inhibiting GABA 
transport are central nervous system depressants and provide protection 
against chemically induced seizures (Brehm et al., 1979). These data support 
the contention that GABA is an important inhibitory neurotransmitter in the 
brain.
Given the distribution of GABAergic neurons in brain, the selectivity of 
GABAergic drugs must be due to neurological differences rather than 
anatomical location. It is possible that more active GABAergic pathways 
would presumably be more sensitive to drugs inhibiting GABA syntheses, 
metabolism or re-uptake, with the response most likely reflecting a functional 
modification in these synapses. Selectivity may also occur at the level of the 
neurotransmitter receptor. Because GABA is a relatively flexible entity, it can 
assume a variety of conformations, making it conceivable that different GABA 
receptors recognize different molecular configurations. GABA receptors were 
initially defined on the basis of their sensitivity to inhibition by bicuculline 
and picrotoxin (Curtis et al., 1971). Recently, evidence has accumulated that 
there may be a group of bicuculline insensitive GABA receptors (Bowery et al.,
1982). These sites are defined on the basis of their sensitivity to (3-P- 
Chlorophenyl GABA (Baclofen), a GABA receptor agonist. Accordingly, 
bicuculline-sensitive, baclofen-insensitive GABA receptors are defined as 
GABA sites, whereas bicuculline-insensitive, baclufen-sensitive response are 
said to be mediated by GABA-B receptors. The third type of GABA receptors,
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autoreceptor is very similar to the A subtype though delta-amino laevulinic 
add is a weak agonist at the autoreceptor, but not at the GABA-A receptor 
(Brennan and Cantrill, 1978, Brennan et al., 1981). This third type of GABA 
receptor, autoreceptor, appears to function as the one which controls the 
release of GABA from its presynaptic terminals (Mitchell and Martin, 1978a, 
Snodgrass, 1978., Arbilla et al 1979, Brennan et al 1981). Other investigators 
have described autoreceptors of the GABA-A type (Mitchell and Martin 1978; 
Brennan et al 1981; Ennis and Minchin, 1988) although whether these are 
coupled to benzodiazepine receptors is unclear; however other results support 
the existence of autoreceptors of GABA-B type (Pittaluga et al 1987). Both 
types may occur; Floran et al, 1988 have presented evidence for differential 
modulation of GABA release by GABA-A and GABA-B autoreceptors in the 
pars compacta and pars reticulata respectively, of the rat substantia nigra.
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3.9 THE BENZODIAZEPINE RECEPTOR AS A MODULATORY U NIT
OF GABAergic NEUROTRANSMISSION
GABAergic inhibitory neurotransmission is mediated in the 
mammalian central nervous system by several kinds of GABAergic neurons 
and by two different types of neuronal response. If GABAergic neurons 
synapse pre-synaptically to axons of other neurons (axo-axonic synapses), 
GABA acts as a presynaptic inhibitory transmitter, probably by depolarizing 
the receptive axon. This kind of pre-synaptic inhibition has been found on the 
endings of primary afferents of spinal cord and cranial nerves. All other kinds 
of GABAergic synapses are axo-somatic or axo-dendritic, where GABAergic 
neurons might be small interneurons (Collateral inhibition or recurrent 
inhibition) or projecting principal neurons (Miller 1987). The GABAergic 
synapses in this second group mediate so-called post-synaptic inhibition and 
account for the majority of GABAergic synapses in the central nervous system 
(Simmonds, 1984). Both kinds of GABAergic inhibition (pre- as well as post- 
synaptic) are mediated by the same GABA receptor subtype, which operates 
by gating a chloride channel of the neuronal membrane. The 
electrophysiological response, however, is different in the case of presynaptic 
inhibition (depolarization) from the case of postsynaptic inhibition 
(hyperpolarization) due to different intracellular chloride concentration at the 
receptive neurons (Simmonds, 1984; Snodgrass, 1983). However, in most 
cases of GABA-mediated responses in the mammalian central nervous system, 
benzodiazepines have been shown to enhance the effects of GABA in spite of 
its pre- or post-synaptic locus of action (Simmonds, 1984).
Since GABAergic inhibition is mediated by changes in the chloride 
conductance of the neuronal membrane, benzodiazepines increase only the
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frequency of chloride channel openings (Barker et al., 1984), while the 
duration of opening events and the channel conductance are not altered. Thus, 
even at the level of the GABA gated chloride channel, the effect of 
benzodiazepines is very specific, in as much as only one out of three functional 
parameters of the chloride channel is altered (Enna and Karbon, 1986).
Pharmacological and biochemical evidence also points to an 
involvement of GABA in the mechanism of action of the benzodiazepines 
(Schallek et al; 1970; Haefely et al 1981). Benzodiazepines are usually more 
potent antagonists against convulsions induced by agents impairing 
GABAergic neurotransmission than against those induced by convulsants 
acting via other neuronal systems (e.g. strychnine as a glycine receptor 
antagonist). Moreover, a large variety of effects of benzodiazepines at the 
electrophysiological, biochemical and pharmacological levels can be blocked 
by relatively low doses of GABA antagonists such as bicuculline and 
pictrotoxin. Finally, in a variety of experimental settings, benzodiazepine 
activity is profoundly lowered when the brain levels of GABA are reduced by 
inhibitors of GABA synthesis (Muller, 1987).
Histological data also indicates that the presence of the benzodiazepine 
receptor in all brain regions correlates strongly with the presence of 
GABAergic nerve terminals (Placheta and Karobath, 1979; Mohler and 
Richards 1983). The final evidence for co-localization of the benzodiazepine 
receptor and the GABA receptor come from the isolation and purification of a 
synaptic macromolecule containing both the benzodiazepine and GABA 
receptor (Schoch et al 1984; Haring et al 1985).
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3.10 THE DISTRIBUTION OF BENZODIAZEPINE RECEPTORS
3.10.1 INTRODUCTION
The benzodiazepines (BZs) are clinically important anxiolytic, muscle- 
relaxant and anticonvulsant drugs (Haelfery et al., 1981). Localization of the 
sites of action of these drugs could provide important clues to defining neural 
pathways involved in the action of benzodiazepines (Nichoff and Whitehouse,
1983).
3.10.2 REGIONAL DISTRIBUTION OF CNS
Almost contemporaneously, Squires and Braestrup (1977) Mohler and 
Okada (1977) reported recognition sites on brain neuronal membranes in vitro, 
to which radio-labelled benzodiazepines (e.g. ^H-diazepam) bind with high 
affinity and selectivity. These sites did not recognise any known 
neurotransmitter, including GABA. The presence of such a neuronally- 
localised entity in the central nervous system, apparently recognising this 
obscure drug molecule, suggested that benzodiazepines might exert their 
action (S) via the so-called benzodiazepine receptor (Waddington, 1982). In 
phylogenetic studies the benzodiazepine receptor appears to have a late 
evolutionary appearance, being absent in invertebrates and lower vertebrates 
but present from higher bony fishes to mammals (Neilsen et al., 1978). While 
originally identified in the rat, it has been characterised in the human brain 
(using post-mortem human brain tissues) and appear to be the most dense in
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the cerebral and cerebellar cortex, of intermediate density in the hippocampus, 
hypothalamus and caudate/putamen and of low density in the pons and 
medulla; there are few sites in white matter such as the corpus callosum 
(Braestrup et al., 1977). However no major differences are present between 
benzodiazepine receptors in animal and human brains. This is supported by 
the data of Sieghart et al. (1985), who compared the affinity and density of 
benzodiazepine receptors in human and rat cortex membranes using two 
different radioligands and he found no differences in ligand affinity. Only 
small differences in maximal binding capacity were found between human 
and rat cortex. Moreover, when the substrate specificities of the 
benzodiazepine receptors in human and animal brain were compared using 
the inhibition constants of a variety of benzodiazepines or related compounds 
for specific radioligand binding, very similar Kj (inhibition constant): values 
were usually found. There is a close correlation between the IC50 values 
(inhibitory concentration 50%) against specific [3H] flunitrazepam binding of a 
large variety of benzodiazepine receptor agonists, antagonists and inverse 
agonists in three areas of rat and human brain. Similar findings have been 
reported by Mohler and Okada (1978).
Braestrup and Neilsen (1982) have emphasised however, on classical 
pharmacological grounds, that before such a binding protein can be validly 
interpreted as a receptor, some functional consequences of its occupation by a 
ligand must be demonstrable. The benzodiazepines exert no readily 
identifiable neurophysiological or neurochemical sequelae at the cellular level 
of their recognition site analogous to those of the known neurotransmitters. 
However, in animal studies the rank order of potency of a wide range of 
benzodiazepines in exerting several pharmacological actions in vivo correlates
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well with their affinity for the brain benzodiazepine recognition site in vitro 
(Braestrup and Squires, 1979). These analyses have been extended to include 
correlations between (1) Clinical anxiolytic potency in man and affinity for the 
human brain benzodiazepine recognition site (Braestrup et al., 1977 and (2) 
Pharmacological potency and the occupancy of binding sites in animals in vivo 
(Paul et al., 1979; Braestrup and Neilsen, 1982). An important criterion for the 
functional relevance of a binding site is its stereospedficity; the 
pharmacologically active isomer of a compound existing as enantiomeric pairs 
should have the greater binding affinity. This has been confirmed in animal 
studies (Waddington and Owen, 1978) which have been able to show that such 
stereospedfic benzodiazepine binding affinity extends to pairs whose 
anxiolytic activity in man resides preferentially in one isomer.
Such evidence does suggest that this recognition/binding site for 
benzodiazepines can be referred to as a receptor, and that it may be intimately 
involved in the mediation of many of the pharmacological and clinical actions 
of benzodiazepines. It is interesting to note that only a small fraction of the 
total number of rodent brain benzodiazepine receptors (25-50%), (Paul et al., 
1979); Braestrup and Neilsen, 1982) need to be occupied for a complete 
anticonvulsant effect. With regard to the dinical anxiolytic, hypnotic and 
anticonvulsant actions of benzodiazepines, the extent of receptor occupation 
required for their manifestation remains unclear (Waddington, 1982)
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Figure 4 Chemical Structure of Clonazepam.
Figure 5 Chemical Structure of Ro 15-1788.
3.10.3 PERIPHERAL BENZODIAZEPINE BINDING SITES
High affinity binding sites for both 3H-diazepam and 3H- 
flunitrazepam are found in the peripheral spinal cord (Young & Kuhar, 
1979), human retina (Borbe et al., 1982), pineal gland (Lowenstein et al.,
1984), human pituitary (Gradison et al., 1982) and in liver, kidney, lung, 
heart and peritoneal mast cell (Braestrup and Squires, 1977, Mohler and 
Okado, 1977; Taniguchi et al., 1989; Davies and Huston, 1981; Gallager et 
al., 1981; Regan et al., 1981).
Peripheral binding sites are distinct from the central receptors in 
their subcellular localization (Anholt et al., 1986) and lack of coupling 
to GABA and chloride channels (Marangos et al., 1982). Both RO 5-4864 
(4-chlordiazepam) and PK 11195 (an isoquinoline carboxamide derivative) 
bind with high affinity to the peripheral sites while their binding to the 
central benzodiazepine receptor is negligible (Benavides et al 1983). The 
binding sites in the peripheral tissues (liver, kidney, lung, heart and 
peritoneal mast cells), however, exhibit quite different recognition 
characteristics from those in the central nervous system. Clonazepam 
(Figure 4) with a very high affinity for the central sites, exhibits a very low 
affinity for the peripheral type site, while the reverse is the case for RO 5- 
4864 (Figure 5) a close structural analogue of diazepam that is inactive 
centrally. It showed a high affinity for the peripheral binding site, whereas 
clonazepam and the benzodiazepine antagonist RO 15-1788, centrally very 
potent drugs, showed no binding affinity to the peripheral site (Braestrup 
and Squire 1977, Mohler et al 1981, Regan et al 1981, Rosenberg et al 1979, 
Taniguchi et al 1980). No function has yet been proposed for these
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peripheral type binding sites though they appear to be associated with the 
mitochondrial outer membrane (Anholt et al, 1986). The peripheral type 
binding site is found in the central nervous system though it may easily be 
resolved in standard binding assay protocols by the use of clonazepam to 
define non-specific binding. 3H-RO-4864 has been used to study the 
peripheral type of benzodiazepine binding site (Marangos et al, 1982, 
Schoemaker et al., 1983, Miongeon et al., 1983, Beaumont et al., 1984). This 
isoquinoline carboxamide derivative PK11195 has also been used for the 
same purpose (Benavides et al, 1983).
Peripheral-type benzodiazepine binding sites exist in human brain, 
with some evidence for a lower density when compared with the density of 
experimental animals (Schoemaker et al., 1982; Owen et al, 1983). The 
density of these sites is slightly elevated in the frontal cortex of Alzheimer 
patients (Owen et al., 1983) and in the putamen of patients who died of 
Huntington’s chorea (Schoemaker et al., 1982), but it is unchanged in the 
frontal cortex of patients who died of dialysis encephalopathy (Kish et al., 
1985b). Since peripheral benzodiazepine binding sites in the central 
nervous system might occur preferentially on glial cells, their increased 
levels in the brains of some patients have been interpreted as a sign of 
gliosis (Owen et al., 1983).
3.10.4 ALBUMIN
Benzodiazepines bind with high degree of specificity, even 
stereoselectivity, to a single site of the human serum albumin molecule
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with particularly high affinities. Since the same single site mediates the 
stereospecific binding of tryptophan and related compounds, this site has 
been termed the indole and benzodiazepine binding site (Muller and 
Wollerty, 1979). This site is of considerable pharmacokinetic relevance 
since it represents one of the two major drug binding sites of human serum 
albumin which are responsible for the interaction of nearly all drugs with 
the albumin molecule. The general properties of this site and their 
pharmacokinetic relevance for benzodiazepines and many other drugs 
have been reviewed (Muller and Wollert, 1979, Sellers et al., 1983, Muller et 
al., 1986a). This site is not involved in any of the pharmacological 
properties of the benzodiazepines except that the plasma binding of these 
drugs contributes to their pharmacokinetics in man (Klotzz, 1984). Thus, 
the indole and benzodiazepine binding site of human serum albumin 
clearly represents a silent receptor (a binding site without any 
physiological response, regardless of whether the ligand is endogenous on 
a drug) and represents an excellent example that specific and even 
stereospecific binding are not per se indicative of biological function.
3.10.5 CONCLUSIONS
Most of benzodiazepine receptors are co-localized with GABA 
receptors. On the other hand, since the central nervous system in man 
contains more GABA receptors than benzodiazepine receptors, it is 
generally assumed that the majority of GABA receptors are not linked to 
benzodiazepine receptors (Bowery et al., 1984).
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The GABA receptors associated with the benzodiazepine receptors 
are always GABA-a  subclass, which can be specifically antagonised by
bicuculline. No evidence exists that GABA-g receptors (which can be
specifically activated by the drug baclofen) are associated with 
benzodiazepine receptors (Bowery et al., 1984).
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4. MEASUREMENT OF MEMBRANE BINDING SITES
4.1 EQUIPMENT AND MATERIALS
Clonazepam
Sodium dihydrogen 
Orthophosphate
Human post-mortem brains
Teflon glass homogeniser
Stirrer
Sodium Carbonate
Copper Sulphate
Sodium Potassium Tartrate
Bovine Serum Albumin 
Sucrose
Folin and Ciocalteu’s Phenol 
Reagent
Centrifuge
Scintillation Counter
Data Processing
Roche Products Limited
B.D.H. Chemicals Limited, Poole, 
England
City Mortuary, Glasgow 
Jacons England
Griffin & George Limited, England
B.D.H. Laboratory Chemicals 
Division, England.
B.D.H. Chemicals Limited, Poole, 
England
B.D.H. Chemicals Limited, Poole, 
England
Sigma Chemical Company
Formachem (Research International) 
Limited
Sigma Chemical Company
Beckman JA 2-21 with JA 20 rotor
Packard 2200 CA Tri-CarbR
Binding Assay - Packard Combicept*”1 
program for IBMR-PCAT.
RIA - Packard Securia T program for 
IBMR -PC AT
Radioligand
Filters
Sdntillant
Pico ’Hang-in' vials
LP3 tubes
43-
N-Methyl [3H]Flunitrazepam 
Amersham International
Whatman GF/B glass microfibre 
filters.
EcosdntR, National Diagnostics 
PackardR.
Luckham Limited., Disposable 
Laboratory Plastics
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4.2 BENZODIAZEPINE RECEPTOR BINDING SITES STUDY
Human post-mortem brain tissue samples (43) and their authentic blood 
samples were collected at the City Mortuary, Glasgow. The collection of the 
samples was done over the period of this research to obtain both cases where 
death was due to benzodiazepine drugs overdose and those where no 
benzodiazepine drugs was involved. The collection of samples entailed visits 
to the City Mortuary on a daily basis, both in the morning and in the 
afternoon. Cases were rejected for a number of reasons including, hepatitis, 
AIDS, lack of blood or where only blood or brain tissue was available.
Blood samples were collected from each case under sterile conditions at 
the time of the autopsy in order to preclude or exclude the presence of 
benzodiazepine drugs.
The distribution of benzodiazepine receptors in human brain tissue 
(frontal cortex, precentral cortex, temporal cortex, occipital cortex, cerebellum 
cortex and hippocampus) was investigated to find the area with the highest 
benzodiazepine brain receptor concentration. Factors which might affect the 
binding site concentration of benzodiazepine receptors in the post-mortem 
human brain tissue such as incubation period, age, sex, cause of death, time of 
death, time interval between death and autopsy and subjects who were on 
benzodiazepine drug therapy prior to death were investigated.
After the protein concentration in each gram of brain tissue had been 
determined, estimation of the receptor densities (Bmax) could be studied. This
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was carried out by binding assay using the Packard Combicept program to 
translate the data for each binding.
The binding technique of high affinity binding is quite simple. The 
labelled ligand was incubated with suitable tissue homogenate. It uses the so- 
called P2-fraction from the brain which is a relatively crude membrane
preparation containing synaptic plasma membranes. After incubation, the free 
and bound ligand were separated by filtration through glass fibre filters. 
Biological membranes together with bound ligand were retained on the glass 
fibre filters by adsorption. The amount of bound ligand was measured by 
scintillation counting.
Specific binding is the amount of binding expected to occur at the 
receptor. Non-specific binding is the remaining binding, i.e. adsorption of the 
ligand to glass filters, the amount of ligand dissolved in the biological 
membranes, and is usually defined as the amount of bound labelled ligand 
which cannot be displaced by excess of unlabelled ligand. Specific binding 
thus, is defined as total binding minus non-specific binding.
4.2.1 PROPERTIES OF AUTHENTIC RECEPTORS
1. Saturability
The great majority of receptors are on the surface of a cell. Since 
there are a finite number of receptors per cell, it follows that a dose- 
response curve for the binding of a ligand should reveal saturability. In
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general, receptor binding is characterized by a high affinity and low 
capacity whereas non-specific binding usually exhibits high capacity and 
low affinity binding which is virtually nonsaturable.
2. Specificity
This is one of the most difficult and important criteria to fulfil, not 
only because of the enormous mass of non-specific binding sites compared 
to receptor sites in tissue but also because of the avidity with which inert 
surfaces bind ligands. For example, substance A binds tenaciously to glass 
and insulin can bind to calcium powder in the nanomolar range. With 
agents that exist as optical isomers, it is of obvious importance to show that 
the binding of the ligand is stereospecific.
Specificity obviously means that one should find receptors only in 
cells known to respond to the particular transmitter or hormone under 
examination. Further, it is a truism that a correlation should be evident 
between the binding affinity of a series of ligands and the biological 
response produced by this series. This correlation is the sine qua non for 
receptor identification.
3. Reversibility
Since transmitters, hormones and most drugs act in a reversible 
manner, it follows that the binding of these agents to receptors should be 
reversible. It is also to be expected that the ligand of a reversible receptor 
should be not only dissociable but recoverable in its natural (i.e. non-
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metabolised) form. This last dictum distinguishes receptor ligand 
interactions from enzyme substrate reactions (Cooper et al 1978).
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4.3 PREPARATION OF SYNAPTOSOMAL MEMBRANES
4.3.1 INTRODUCTION
Neural tissue is composed of neurons and their support cells, the glia. 
Neurones are notable for their highly elaborate shapes and the possession of 
long and often branching processes which intermingle extensively with each 
other and with glia. Such cells do not survive homogenization intact; the cell 
bodies are sheared from their processes which break up into discrete 
fragments. The plasma membranes of cell fragments may reseal to form 
osmotically active particles and when such particles contain the organelles of 
the synapse they are known as synaptosomes (Gordon, 1987).
Subcellular fractions enriched in synaptosomes are sufficiently pure to 
permit the study of certain physiological and pharmacological aspects of 
synaptic function. These fractions are not, however, completely free of 
contaminating particles particularly axonal, myelinated and unmyelinated, 
and mitochondria, nor are they homogeneous in one type of synapse (Cotman, 
1974). This has important consequences for the interpretation of experiments 
using synaptosomes for it is extremely difficult to assign a particular property 
of the fraction to a constituent, except under certain conditions such as when 
investigating the release of radiolabelled neurotransmitter that is known to 
accumulate only in that constituent.
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Unlike synaptosomal fractions, subcellular components derived from
synaptosomes such as post-synaptic densities and synaptic vesicles are
sufficiently pure for biochemical analysis.
4.3.2 PREPARATION
1. One gram of post-mortem human brain tissue was homogenised in 
10 ml of ice-cold 0.32M sucrose solution using 20 strokes of a teflon- 
glass homogeniser. (Sucrose is ideal in many respects as an isolation 
medium, the concentration used to isolate synaptosomes is hypertonic 
and consequently synaptosomes lose water and are very shrunken 
when recovered from the gradient).
2. Centrifuge at 3500 rpm for 10 minutes at 4°C.
3. Discard the pellet, the remaining supernatant is centrifuged for 
20 minutes, spin speed 15,000 rpm, at 4°C.
4. Discard the supernatant and measure the weight of the pellet.
5. Homogenise the pellet in 10 ml of ice-cold assay buffer (25 mm sodium 
phosphate assay buffer, pH 7.4)
6. Transfer to a suitable vial and store at -20°C until required 
(see Figure 6).
Figure 6 Preparation Of Synaptosomal Membranes.
RECEPTOR PREPARATION 
BRAIN /SUCROSE BUFFER
HOMOGENISE
1
CENTRIFUGE 3500rpm 
S U P E R N m N T ^ ^ ^  PELLET - DISCARD
CENTRIFUGE 15000rpm
PELLET WEIGH SUPERNATANT DISCARD 
1
ASSAY BUFFER — ►  RESUSPEND —►  STORE -20C
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4.4 PROTEIN DETERMINATION
4.4.1 INTRODUCTION
Proteins are readily determined by the colorimetric method of 
Lowery et al (1951). It is carried out using bovine serum albumin to prepare 
the standard curve. The coloured complex which is measured in a 
spectrophotometer directly relates to the protein concentration. It is due to 
tyrosine and tryptophan residues in the protein complexing with the alkaline 
copper-phenol reagent. For each tissue sample, determine the protein present 
(in duplicate) and a standard curve (in duplicate).
4.4.2 REAGENTS REQUIRED
- Sodium carbonate, 2% w/V, in 0.1M NaOH.
- Copper sulphate (hydrate), 1% w /v, in water.
- Sodium potassium tartrate, 2% w /v, in water.
4.4.3 METHOD
(a) Tissue Sample
1. Dilute the tissue sample 1:100 with 0.5M NaOH.
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2. Take 0.2, 0.4, 0.6, 0.8 and 1.0 ml of the diluted tissue sample and 
make up to a final volume of 1ml with 0.5M NaOH. Prepare a blank 
containing 1.0 ml of 0.5M NaOH instead of the tissue sample.
3. Add 5 ml of copper reagent to all samples (including the blank), 
mix thoroughly by vortexing, and allow to stand for 10 minutes.
4. Add 0.5 ml of IN Folin reagent, mix immediately and completely 
and stand for 30 minutes.
5. Read absorbance at 540 nm on a spectrophotometer, after zeroing 
the instrument on the blank.
6. The tissue protein content can then be directly interpolated from 
the standard curve below.
(b) Bovine Serum Albumin Standard Curve
1. Make a stock solution of bovine serum albumin (100 pg/ml-1) in
0.5M NaOH.
2. Take 0, 0.2, 0.4, 0.6, 0.8 and 1.0 ml of the above solution 
(equivalent to 0,20, 40, 60, 80, 100 ug protein ml-1 respectively) 
and make up to a final volume of 1 ml with 0.5 NaOH.
3. Process the standard curve as described on (a) above starting 
from (3.) and continuing to (5.).
4. Construct the standard curve by plotting absorbance against 
bovine serum albumin (ug) per assay (Figure 7 and Table 3).
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Figure 7 Protein Concentration Curve.
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Table 3: Data For Standard Curve For Protein Assay
|ig/protein/mZ Absorbance Average Absorbance
oio 0.08
0.08
0 -0 0.08
0.2 0.12
0.12
0.2 0.12
0.4 0.17
0.17
0.4 0.17
0.6 0.20
0.20
0.6 0.20
0.8 0.24
0.255
0.8 0.25
1.0 0.32
0.31
1.0 0.30
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NOTES
1. Prepare the stock bovine serum albumin and copper reagent fresh on
day of use.
2. If the tissue protein content absorbance values read higher than the
standard curve range, further dilute the tissue sample to 1:50 and 
repeat the determination.
3. If a spectrophotometer is not available to read 450 nm, absorbances
can also be read at 750 nm.
4. Copper reagent is prepared fresh by mixing the above sodium
carbonate, copper sulphate and sodium potassium tartrate solutions 
in the ratios of 200:2:2 by volume respectively).
Bovine serum albumin, 100 pg /m l1 in 0.5M NaOH.
OTHER MATERIALS
- vortex mixer.
- spectrophotometer capable of reading absorbance at either 750 nm 
or 540 nm.
After the human brain tissue was homogenised and centrifuged 
twice as described earlier, the weight of each pellet was determined and 5 
ml assay buffer (25 mM sodium dihydrogen orthophosphate, pH 7.4) was 
added to each pellet and vortexed well in order to display protein 
concentration in each pellet (P2 = which contain synaptic membrane) using
the Lowery method.
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Estimation of protein concentration of each pellet (from human brain 
tissue) was determined at two dilution levels (using 0.5M NaOH), 1/10 and 
1/50, in order to obtain a more accurate determination of its concentration. 
Tables 4 and 5 indicate the figures from the two dilutions 1/10 and V50 of 
the human brain receptor preparation used, from which human brain 
protein concentration of the pellet can be calculated.
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Table 4: U.V. Absorbance of Known Dilutions of the Receptor
Preparation Pellet (protein content of 1/10 dilution of 
receptor preparation pellet)
Samples
1/10
Volume of Average Protein content
Pellet Absorbance mg pt1ml of original
Solution * Absorbance sample dilution
mg/ml
0.2 0.15
0.145 31 155
0.2 0.14
0.4 0.19
0.195 54 135
0.4 0.20
0.6 0.26
0.26 83 138
0.6 0.26
0.8 0.32
0.315 107 133.7
0.8 0.31
1.0 0.38
0.375 134 134
1.0 0.37
* this volume was diluted to 1 ml with 0.5M NaOH
Average 139.2
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Table 5: U.V. Absorbance of Known Dilutions of the Receptor
Preparation Pellet (protein content of 1/50 dilution of 
receptor preparation pellet)
Samples
1/50
Volume of Average Protein content
Pellet Absorbance mg pt/raZ of original
Solution * Absorbance sample dilution
mg/ml
0.2 0.09
0.09 7 35
0.2 0.09
0.4 0.10
0.095 9 22.5
0.4 0.09
0.6 0.11
0.105 14 23.3
0.6 0.10
0.8 0.11 0.115
18 22.5
0.8 0.12
1.0 0.13
0.13 25 25
1.0 0.13
Average 25.67.
* this volume was diluted to 1 ml with 0.5M NaOH
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4.5 EQUILIBRIUM STUDY (INCUBATION PERIOD)
4.5.1 INTRODUCTION
The object of the experiment was to find the optimal incubation time 
and to obtain the association curve for where the benzodiazepine receptors 
and 3h  flunitrazepam reach equilibrium. It was also designed to determine 
the stable period for the receptor/ligand equilibrium.
Human post-mortem brain tissue sample was obtained at autopsy from 
a female aged 28 years, who died from chest and abdominal injuries (RTA). A 
blood sample was taken from the deceased and analysed for the presence of 
benzodiazepine drugs using both radio-immunoassay and HPLC with 
negative results. The grey matter from the frontal cortex was freshly dissected 
taking care to avoid contamination by white matter.
4.5.2 BUFFER AND STANDARD PREPARATION
Sodium dihydrogen orthophosphate anhydrous (NaH2P04 - m.wt 
119.98) buffer was made up by dissolving 39.1 grams of NaH2P04 in deionised
water and made up to one litre producing a buffer concentration of 0.5M. This 
was adjusted with sodium hydroxide (NaOH) to pH 7.4. Further dilutions 
with deionised water were made to produce a working solution of 25 mM.
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All [3h ] flunitrazepam (0.63-20nM) dilutions were made up with 
25 mM sodium dihydrogen orthophosphate buffer, pH 7.4.
A stock solution containing clonazepam was prepared by dissolving 
10 mg of clonazepam drug in a few drops of methanol and then diluting to 
10 ml with deionised water to produce a stock standard clonazepam solution 
of 1 mg/ml. Further dilution with deionised water was made to produce a 
working solution of 20 uM.
4.5.3 REMOVAL OF BRAIN
The final part of the autopsy is the removal of the brain. The incision on 
either side of neck is continued upwards and slightly posteriorly over the top 
of the head. It is important to part the hair anteriorly and posteriorly on either 
side of the incision to avoid cutting off large pieces of hair. The front and rear 
flaps of the skin of the scalp are then reflected.
An incision is then made around the insertion of the temporalis muscle 
into the side of the skull.
The vault of the skull is removed by a saw cut through the calvaria 
which should be made immediately above the supra-orbital ridge and 
continued horizontally round the skull to the occiput until the underlying dura 
is reached. An electric or handsaw can be used for this purpose.
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A T-piece key will usually prise the vault off the base of the skull, 
although a mallet and chisel might be needed to loosen imperfectly sawn 
places. If the dura mater adheres to the inner aspect of the vault, it can 
sometimes be separated with a flat dissector or the dura may have to be 
incised and removed with the vault. A midline sagittal incision into the dura 
should then be made, to open the superior longitudinal sinus. The dura is 
then removed by cutting into its lateral parts. The cuts are made laterally 
where the brain is least in contact with the dura, and is consequently less likely 
to be damaged as the dura is removed.
Tilting the head away from the lateral incision further prevents injury to 
the brain which falls away from the cut. The dura is then reflected over the 
top of the brain and its attachment to the skull base anteriorly in the middle 
line is divided. It can then be pulled backwards over the back of the brain. 
The brain is then removed.
This is achieved by gently raising the frontal poles and with even 
greater care, the delicate olfactory nerves are lifted off the base of the skull. 
This is the first cranial nerve and the remaining eleven pairs are divided 
successively.
After this has been done, the vertebral arteries on either side are cut and 
the lower medulla oblongata (the upper end of the spinal cord) is transected.
The brain can then be lifted gently out of the skull. Before further 
dissection of the brain at the time of autopsy it is first inspected carefully, then 
the upper pons is divided freeing the hind brain. The cerebral hemispheres
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are examined by transverse cuts across them. The slices of brain can be laid 
out sequentially on a large tray for demonstration purposes (Gresham and 
Turner, 1979).
4.5.4 PROTEIN DETERMINATION
Protein concentration in each gram of human frontal cortex tissue (grey 
matter) was determined by the colorimetric method of Lowery as described 
in 4.4
4.5.5 SATURATION CURVE ANALYSIS OF 
t3h i FLUNITRAZEPAM BINDING
The receptor binding assay used in this study for investigating the 
binding site concentration has been modified from Horton et al., 1982, 1988. 
The protein concentration of the homogenate was adjusted by dilution with 25 
mM sodium dihydrogen orthophosphate buffer to produce 0.15 mg/ml.
Total Binding Assay
12 pairs of LP3 tubes were set up to enable each [^H] flunitrazepam 
concentration to be assayed in duplicate. 100 ul 3H-flunitrazepam 
(concentration ranging from 0.6-20 nM) was incubated with 800 ul 
(approximately 0.15 mg protein) of membrane preparations (see page ??) and 
100 ul of 25 mM sodium phosphate buffer (pH 7.4) after each tub was
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vortexed, to ensure thorough mixing. They were incubated at room 
temperature (20°C) for different times 0, 30, 60, 90, 120 and 150 minutes. The 
incubation mixture was rapidly filtered through a Whatman GF/C glass fibre 
filter with suction. The filter and tube were washed with an additional 5 ml 
of 25 mM sodium phosphate buffer (pH 7.4). The radioactivity retained on the 
filters were placed into pico vials, 4 ml of sdntillant (Ecosdnt) was added and 
vials mixed well. Each tube which contained the radioactivity retained on the 
filter was estimated by counting for one minute and gave the DPM of the 
bound radioligand (see Figure 8).
Non-Specific Binding Assay
Twelve pairs of LP3 tubes were set up to enable each [^H] 
flunitrazepam concentration to be assay in duplicate. 100 ul ^H-flunitrazepam 
(concentration ranging from 0.6-20 nM) was incubated with 800 ul 
(approximately 0.15 mg protein) of membrane preparations and 100 ml of 
donazepam (2 uM) after each tub was vortexed, to ensure through mixing. 
They were incubated at room temperature (20°C) for different times 0, 30, 60, 
90,120 and 150 minutes. The incubation mixture was rapidly filtered through 
a Whatman GF/C glass fibre filter with suction. The filter and tube were 
washed with an additional 5 ml of 25 mM sodium phosphate buffer assay 
(pH 7.4). The radioactivity retained on the filters were placed into pico vials, 
4 ml of sdntillant (Ecosdnt) was added and vials mixed well. Each tube which 
contained the radioactivity retained on the filter was estimated by counting for 
one minute and gave the DPM of the bound radioligand (Figure 8).
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Figure 8.
BINDING ASSAY
MEMBRANE HOMOGENATE 
PROTEIN CONCENTRATION
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(2) HOMOGENATE+FNZ+CLONAZEPAM
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FILTER 
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COUNT TRAPPED RADIO-ACTIVITY 
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4.5.6 RESULTS AND DISCUSSION
0.15 mg/ml protein concentration was used as a working concentration 
for the benzodiazepine binding assay study to assess the suitable incubation 
time of prepared receptors.
The receptor binding assay consisted of an osmotically shocked crude 
synaptosomal preparation which was incubated for different times 0, 30, 60, 
90, 120 and 150 minutes at room temperature. After incubation the receptor - 
ligand complex was separated by filtration through glass fibre filters and 
measured to determine the maximal binding concentration (Bmax) by the 
combicept program which incorporates both an orthogonal weighting scheme 
and the Rosenthal correction for NSB (non-specific binding) subtraction 
(Combicept, Packard).
Subtracting the non-specific DPM results from the total bound DPM 
results gives the DPM for the specifically bound [^Hjflunitrazepam as 
revealed in Table 6.
These results together with the DPM of the total radioligand added are 
transformed by the Combicept Program, to determine maximal binding 
concentration as shown in Figure 9 (from data in Table 7). Using the 
orthogonal weighting scheme it statistically eliminates some of the errors 
encountered during data transformation to the saturation curve which is still 
recommended as the best way of analysing data for a binding study.
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Figure 10 (from data of Table 8) demonstrates how long the incubates 
take to reach equilibrium (which is 30 minutes) and how long the incubates 
could be left before the equilibrium began to disrupt (which is after 
60 minutes).
It can be seen from this experiment that the incubation period of 
benzodiazepine binding can be started investigated 30 minutes minimum and 
at 60 minutes maximum (receptor viability). This 30 minute period where the 
equilibrium is stable is sufficient to filter a large number of samples before the 
receptor/ligand binding is disrupted (radiolysis).
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Table 6: Binding assay for total, non-specific and specific binding of 
[3H] Flunitrazepam to benzodiazepine receptors in human 
brain tissue. (Frontal cortex region).Incubation 30 minutes.
No. Std. Total bound 
DPM
Non-specifically bound 
DPM
Specifically bound 
DPM
1 2 5 1 2 . 7
X = 2 6 4 4 .8
8 1 . 6
X = 9 8 .2 X - 2 5 4 6 . 6
1 2 7 7 6 . 8 1 1 4 . 7
2 4 9 1 9 . 4
X = 5 0 0 9 .9
1 2 6 . 6
X s 1 0 2 . 3 X = 4 9 0 7 . 6
2 5 1 0 0 . 3 7 7 . 9
3 9 2 1 5 . 6
X = 9 1 4 7 .6
1 2 5 . 3
X = 1 4 4 .6 X = 9 0 0 3
3 9 0 7 9 . 6 1 6 3 . 8
4 1 3 6 3 1 . 0
X = 1 3 4 9 6 .8
3 2 4 . 7
X = 4 5 2 .6 X = 1 3 0 4 4 . 2
4 1 3 3 6 2 . 6 5 8 0 . 6
5 1 7 1 2 9 . 4
X = 1 6 5 5 1 .5
7 6 8 . 1
X = 8 1 8 .8 X = 1 5 7 3 2 . 7
5 1 5 9 7 3 . 6 8 6 9 . 5
6 2 6 7 3 4 . 6
X = 2 4 1 1 7 .0
1 4 2 4 . 1
X = 1 2 8 7 .3 X = 2 2 8 2 9 . 7
6 2 1 4 9 9 . 4 1 1 5 0 . 5
Average.
DPM= Disintegration/minute.
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Figure 9 Saturation Curve 
(Clonazepam).
0 . 1 3 4
0 . 1 0 7
0 . 0 8 1
0 . 0 5 4
0 . 0 2 7
1 1 . 9 57 . 1 7 3 9 . 5 6 44 . 7 8 22 . 3 9 1
sb-Specifically bound tritiated flunitazepam. 
st-total tritiated flunitazepam.
Table 7 Experimental Binding Assay .Incubation 30 Min. 
(Rosenthal NSB Correction)
Point Sb St
1 0.140 0.334
2 0.264 0.681
3 0.0482 1.345
4 0.071 2.581
5 0.085 5.295
6 0.122 10.868
St-Total tritiated flunitrazepam added (nM). 
Sb-Specifically bound tritiated flunitrazepam.
BI
ND
IN
G 
SI
TE
 
C
O
N
C
. 
(fm
ol
/m
g 
Pr
ot
ei
n)
-70-
Figure 1C Binding Site Concentration Against Time.
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Table 8 Effects of incubation time against binding site 
concentration.
Time (min) Binding site concentration 
(fmol/mg protein)
Average
0 800 775
750
30 1253 1245.5
1238
60 1286 1283
1276
120 1138 1150
1162
150 1067 983.5
900
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4.6 REGIONAL DISTRIBUTION OF BENZODIAZEPINE RECEPTORS 
IN HUMAN BRAIN TISSUE
4.6.1 INTRODUCTION
Human brain tissue was obtained at autopsy from four females and two 
males (all died for a variety of reasons including multiple injuries due to road 
traffic accident, hypertension, coronary artery atheroma, acute alcohol 
intoxication, hanging and acute myocardial infarction. Their ages ranged from 
15 to 68 years). All were shown to be free of benzodiazepine drugs by case 
history and analysis using HPLC and RIA.
In order to find the site of highest densities of benzodiazepine receptors 
in human brain tissue, six sites were studied - frontal lobe cortex, postcentral 
cortex, temporal cortex, occipital cortex, cerebellum and hippocampus 
(Figure 11).
4.6.2 REMOVAL OF BRAIN
Six human brain tissue samples were removed (as described in 4.5.3) 
and dissected rapidly. The cortices were collected under sterile condition 
(white matter was avoided).
Figure 11.
- 7 3 -
! Postcentral gyrusOccipital
lobe
Frontal
lobe
Temporal lobe
Cerebellum
Frontal lobe
Temporal lobe
Hippocampus
Cerebellum
4.6.3 PREPARATION OF SYNAPTOSOMAL MEMBRANES
Each gram of brain tissue was homogenized in 10 ml of ice cold 0.32M 
sucrose solution using 20 strokes of a Teflon-glass homogeniser. The 
homogenate was centrifuged at 3500 rpm for 10 minutes at 4°C. The 
supernatant was centrifuged again at 15000 rpm at 4°C. The resultant pellet 
(crude P2 fraction) was suspended in 10 ml assay buffer (25 mM dihydrogen-
orthophosphate buffer pH 7.4). The membranes were frozen until they were 
used for the binding studies.
4.6.4 PROTEIN DETERMINATION
Protein concentration in each gram of human brain area (frontal cortex, 
post central cortex, occipital cortex, temporal cortex, cerebellum cortex and 
hippocampus) was determined by the colorimetric method of Lowery as 
described in 4.4.
4.6.5 BUFFER AND STANDARD PREPARATION
Buffer and standard preparation was carried out as described in 4.5.2.
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4.6.6 BINDING STUDY
The receptor binding assay study used in this research, has been 
modified from the technique of Horton et al. (1982, 1988). It was used to 
determine the number of receptors available for binding in a preparation of 
brain tissues (frontal cortex, post central cortex, occipital cortex, temporal 
cortex, cerebellum and hippocampus).
Non-Specific Binding
Aliquots of homogenate were incubated in duplicate for 30 minutes at 
room temperature 20 °C in a total volume of 1 ml, as follows:
3[H] FNZ (85 Ci/mmol) was obtained from New England nuclear. 
Clonazepam (Roche) was initially dissolved in ethanol (1 m g /m l) and made 
up to the required concentration (2 uM) with buffer (25 mM sodium 
dihydrogenorthophosphate buffer pH 7.4).
Bound radioactivity was separated on Whatman GF/B glass fibre filters
under vacuum and the filters were washed with 5 x 1 ml of assay buffer (25 
mM sodium dihydrogenorthophosphate buffer pH 7.4). The filters were
800 ul homogenate 
100 ul clonazepam 
100 ul 3[H] FNZ
Final Concentration 
0.15-0.20 mg/ml 
2 uM
0.6-20 nM
- 7 6 -
placed into Pico vials, 4 ml of sdntillant (Ecosdnt) was added and the trapped 
radioactivity determined by liquid scintillation counting (Packard) to find the 
DPM of the bound radioligand.
Total Binding
Aliquots of homogenate were incubated in duplicate for 30 minutes at 
room temperature (20°C) in a total volume of 1 ml as follows:
Final Concentration 
800 ul homogenate 0.15-0.2 mg/ml
100 ul assay buffer
100 ul [3h ] FNZ 0.6-.20 nM
Non-specific binding was treated as total binding (as mentioned above).
12 pairs of LP3 tubes were set up to enable each [^H] flunitrazepam 
concentration to be assayed in duplicate. They were incubated at room 
temperature (20 °C) for 30 minutes. The incubation mixture was filtered 
through a Whatman GF/C glass filter with suction. The filter and tube were 
washed with an additional 5 ml of 25 mM sodium phosphate buffer assay (pH 
7.4). The filters were placed into pico vials, 4 ml of sdntillant (ecosdnt) was 
added and vials mixed well. The trapped radioactivity was estimated by 
counting for one minute as before to find the DPM of the bound radioligand.
The DPM of total added label was determined by addition of 100 ul of 
each radioligand concentration directly to 4 ml of sdntillant which was 
counted for one minute.
4.6.7 RESULTS AND DISCUSSION
Using the general binding method described above, the distribution of 
benzodiazepine receptors has been investigated in human brain tissue. The 
receptor binding assay consisted of an osmotically shocked crude synaptosomal 
preparation which was incubated for 30 minutes at room temperature. After 
incubation the receptor-ligand complex was separated by filtration through glass 
fibre filters and measured to determine the maximal binding concentration in 
frontal cortex, post-central cortex, occipital cortex, hippocampus, cerebellum 
cortex and temporal cortex by the CombiceptR programme as before.
Subtracting the non-specific DPM results from the total bound DPM 
results gives the DPM for the specifically bound [^H]flunitrazepam as 
highlighted in Tables 10-15.
The results together with the DPM of the total radioligand added are 
transformed by the Combicept program, to determine maximal binding 
concentration (Bmax) as illustrated in Figures 13-18 from data in Tables 16-21.
This experiment showed that highest densities of binding sites were to 
be found in the frontal lobe cortex (grey matter) area. Intermediate densities 
were found in most other areas (post-central cortex, occipital cortex, 
hippocampus) and low densities were found in cerebellum cortex and 
temporal cortex (Table 9 and Figure 12). This study agrees with other 
investigators and supports the concept that benzodiazepines are bound to 
specific receptor sites in areas of the central nervous system, which are most 
likely their sites of action.
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Table 9 Regional distribution of benzodiazepine receptors in 
human brain tissue.
No Brain
region
Maximum specific binding site 
(fmol/mg protein)
statistics
1 Frontal cortex 1341 1216 1325 1362 1126 1300 X=1278.4
S.D=90.2
c.v=7.05%
2
Postcentral
cortex 1050 981 1062 1170 1098 998 X=1059.8 
S.D=68.89 
c.v=6J50%
3 Occipital
cortex
1016 1092 927 1060 1090 960 X-1024.2
S.D=69.05
c.v=6.74%
4 Hippocampus 841 910 807 980 896 900 X=889
S.D=6
cv=0.7%
5 Cerebellum 662 542 613 590 642 660 X=618.2
S.D=46.6
c.v=75%
6 Temporal
cortex
638 700 590 610 561 531 X=605
S.D=59.6
c.v=9.8%
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F ig u re  12 Regional Distribution of B enzodiazepine Receptors
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Table 10: Binding assay for total, non-specific and specific binding of 
[3H] Flunitrazepam to benzodiazepine receptors in human 
brain tissue.(Frontal cortex region).
No. Std. Total bound 
DPM
Non-specifically bound 
DPM
Specifically bound 
DPM
1 2 5 1 2 . 7
X = 2 6 4 4 .8
8 1 . 6
X = 9 8 .2 X = 2 5 4 6 .6
1 2 7 7 6 . 8 1 1 4 . 7
2 4 9 1 9 . 4
X = 5 0 0 9 .9
1 2 6 . 6
X - 1 0 2 . 3 X - 4 9 0 7 . 6
2 5 1 0 0 . 3 7 7 .9
3 9 2 1 5 . 6
X = 9 1 4 7 .6
1 2 5 . 3
X = 1 4 4 .6 X = 9 0 0 3
3 9 0 7 9 . 6 1 6 3 . 8
4 1 3 6 3 1 . 0
X = 1 3 4 9 6 .8
3 2 4 . 7
X = 4 5 2 .6 X = 1 3 0 4 4 . 2
4 1 3 3 6 2 . 6 5 8 0 . 6
5 1 7 1 2 9 . 4
X = 1 6 5 5 1 .5
7 6 8 . 1
X = 8 1 8 .8 X = 1 5 7 3 2 . 7
5 1 5 9 7 3 . 6 8 6 9 . 5
6 2 6 7 3 4 . 6
X = 2 4 1 1 7 .0
1 4 2 4 . 1
X s= 1 2 8 7 .3 X = 2 2 8 2 9 . 7
6 2 1 4 9 9 . 4 1 1 5 0 . 5
% =A verage
D P M =  D is in te g r a t io n /m in u te .
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Table 11: Binding assay for total, non-specific and specific binding of 
[3H] Flunitrazepam to benzodiazepine receptors in human 
brain tissue (Post-central cortex region).
No. Std. Total bound 
DPM
Non-specifically bound 
DPM
Specifically bound 
DPM
1 1 5 3 9 . 8
% = 1 6 3 3 .8
5 9 . 8
X = 8 0 .4 X = 1 5 5 3 0 4
1 1 7 2 7 . 8 1 0 1 . 1
2 3 2 3 6 . 6
X = 3 1 8 0 .5
1 8 1 . 5
X = 1 4 2 .1 X = 3 0 3 8 .4
2 3 1 2 4 . 4 1 0 2 . 7
3 4 8 3 0 . 7
X = 5 3 0 8 .9
1 4 1 . 2
X = 1 7 6 .8 X = 5 1 3 2 .1
3 5 7 8 7 . 0 2 1 2 . 4
4 8 5 0 6 . 5
X = 8 5 3 7 .0
4 5 8 . 9
X = 4 7 2 .2 X = 8 0 6 4 .8
4 8 5 6 7 . 6 4 8 5 . 5
5 1 2 7 1 9 . 4
X = 1 2 0 7 8 .9
8 4 2 . 6
X = 1 0 4 3 .6 X = 1 1 0 3 5 .3
5 1 1 4 3 8 . 3 1 2 4 4 . 5
6 1 4 2 1 1 . 9
X = 1 4 4 5 9 .1
1 8 3 6 . 8
X = 1 6 3 9 .5 X = 1 2 8 1 9 .6
6 1 4 7 0 6 . 4 1 4 4 2 . 2
% =A verage.
D P M =  D is in te g r a t io n /m in u te .
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Table 12:Binding assay for total, non-specific and specific binding of 
[3H] Flunitrazepam to benzodiazepine receptors in human 
brain tissue (Occipital cortex region).
No. Std. Total bound 
DPM
Non-specifically bound 
DPM
Specifically bound 
DPM
1 1 6 7 3 . 6
X = 1 8 1 8 .9
2 2 3 . 9
X = 2 2 3 .2 X = 1 5 9 5 .7
1 1 9 6 4 . 2 2 2 2 . 5
2 2 7 6 2 . 4
X = 2 7 9 6 .2
5 0 1 . 2
X = 3 7 1 .5 X = 2 4 2 4 .7
2 2 8 3 0 . 1 2 4 1 . 9
3 4 0 9 2 . 6
X = 4 5 3 4 .9
7 5 9 . 9
X = 7 6 8 .5 X = 3 7 6 6 .4
3 4 9 7 7 . 3 7 7 7 . 1
4 7 2 9 7 . 0
X = 6 4 4 9 .5
1 6 2 4 . 5
X = 1 5 5 0 .8 X = 4 8 9 8 .7
4 5 6 0 1 . 9 1 4 7 7 . 2
5 9 6 0 7 . 6
X = 9 4 9 3 .7
4 1 3 7 . 2
X = 2 6 9 8 .9 X = 6 7 9 4 .8
5 9 3 7 9 . 9 1 2 6 0 . 5
6 1 1 7 8 8 . 4
X = 1 2 5 6 4 .6
3 5 9 3 . 8
X = 3 5 5 8 .0 X = 9 0 1 1 6
6 1 3 3 4 0 . 8 3 5 2 2 . 2
X = A v e r a g e .
D P M =  D is in te g r a t io n /m in u te .
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Table 13: Binding assay for total, non-specific and specific binding of 
[3H] Flunitrazepam to benzodiazepine receptors in human 
brain tissue (Hippocampus region).
No. Std. Total bound 
DPM
Non-specifically bound 
DPM
Specifically bound 
DPM
1 1 3 5 1 . 7
X = 1 2 4 2 .4
1 5 6 . 0
X = 1 5 1 .7 X = 1 0 9 0 .7
1 1 1 3 3 . 1 1 4 7 . 4
2 2 1 4 3 . 9
X = 2 0 6 9 .4
2 9 7 . 8
X = 2 7 5 .7 X = 1 7 9 3 .7
2 1 9 9 4 . 8 2 5 3 . 6
3 3 0 2 5 . 5
X = 3 1 0 6 .4
1 1 9 0 . 2
X = 8 6 5 .5 X = 2 2 4 0 .9
3 3 1 8 7 . 2 5 4 0 . 7
4 4 4 1 3 . 8
X = 4 7 1 5 .5
9 5 7 . 0
X = 9 9 6 .5 X = 3 7 1 9 .0
4 5 0 1 7 . 3 1 0 3 6 . 0
5 7 0 1 5 . 2
X = 7 0 8 3 .4
1 5 3 9 . 0
X = 1 5 6 0 .9 X - 5 5 2 2 . 5
5 7 1 5 1 . 5 1 5 8 2 . 9
6 9 6 5 9 . 3
X = 1 0 6 1 6 .7
3 2 6 1 . 9
X = 3 6 9 3 .4 X = 6 9 2 3 .3
6 1 1 5 7 4 . 0 4 1 2 4 . 9
% =A verage.
D P M =  D is in te g r a t io n /m in u te .
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Table 14: Binding assay for total, non-specific and specific binding of 
[3H] Flunitrazepam to benzodiazepine receptors in human 
brain tissue (Cerebellum cortex region).
No. Std. Total bound 
DPM
Non-specifically bound 
DPM
Specifically bound 
DPM
1 5 2 0 8 . 2
% = 5 2 0 8 .2
1 2 7 . 0
X - 1 2 7 . 2 X = 5 0 8 1
1 5 2 0 8 . 2 1 2 7 . 3
2 7 9 7 9 . 2
% = 7 9 8 8 .6
5 9 1 . 9
X = 6 3 4 .6 X = 7 3 5 4
2 7 9 9 8 . 1 6 7 7 . 4
3 1 2 1 7 8 . 6
X = 1 1 8 7 8 .0
2 7 0 . 6
X = 2 9 4 .4 X = 1 1 5 8 3 .6
3 1 1 5 7 7 . 4 3 1 8 . 3
4 1 7 5 3 9 . 3
X = 1 8 2 4 1 .0
2 5 1 5 . 9
X = 1 7 6 6 .7 X = 1 6 4 7 4 .3
4 1 8 9 4 2 . 8 1 0 1 7 . 5
5 2 3 0 2 8 . 6
X = 2 3 6 8 7 . 8
1 2 8 5 . 0
X = 1 2 8 5 .2 X = 2 2 4 0 2 .6
5 2 4 3 4 7 . 1 1 2 8 5 . 3
6 2 8 4 8 8 . 0
% = 2 8 4 8 8 .0
1 1 7 4 . 6
X = 1 6 5 1 .4 X = 2 6 8 3 6 .6
6 2 8 4 8 8 . 0 2 1 2 8 . 2
X = A v era g e .
D P M =  D is in te g r a t io n /m in u te .
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Table 15: Binding assay for total, non-specific and specific binding of 
[3H] Flunitrazepam to benzodiazepine receptors in human 
brain tissue (Temporal cortex region).
No. Std. Total bound 
DPM
Non-specifically bound 
DPM
Specifically bound 
DPM
1 1 0 5 1 . 5
X = 9 6 7 .2
7 0 . 0
X - 6 0 . 3 X = 9 0 6 .9
1 8 8 5 . 0 5 0 . 5
2 1 6 6 0 . 0
X = 1 7 0 7 .2
5 1 . 9
X - 5 6 . 2 X - 1 6 5 1
2 1 7 5 4 . 4 6 0 . 4
3 2 6 0 5 . 3
X = 2 6 7 7 .4
1 4 4 . 9
X = 1 3 4 .1 X = 2 5 4 3 .3
3 2 7 4 9 . 6 1 2 3 . 2
4 4 5 3 1 . 7
X = 4 1 9 0 .4
2 4 4 . 5
X = 3 5 4 .9 X = 3 8 3 5 . 5
4 3 8 4 9 . 1 4 6 5 . 3
5 5 9 3 5 . 0
X = 6 1 4 9 .0
4 4 4 . 1
X = 4 8 3 .8 X = 5 6 6 5 . 2
5 6 3 6 3 . 0 5 2 3 . 5
6 8 4 5 7 . 1
X = 7 9 5 0 .4
1 1 0 8 9 . 0
X = 1 2 3 0 .6 X = 6 7 1 9 8
6 7 4 4 3 . 7 1 3 7 2 . 3
X = A v era g e .
D P M =  D is in te g r a t io n /m in u te .
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Figure 13 Saturation Curve.Frontal Cortex.
Sb
0.122
0 . 0 8 5
max.
0 . 0 7 1
0 . 0 4 8 2
0.00
0.681 2.581 10.8680.00
St
st-Total tritiated flunitiazepam Added (nM).
sb-Specifically bound tritiated flunitrazepam.
Table 16 Experimental Binding Assay.Frontal Cortex.
(Rosenthal NSB Correction)
Point Sb St
1 0.140 0.334
2 0.264 0.681
3 0.0482 1.345
4 0.071 2.581
5 0.085 5.295
6 0.122 10.868
S t-T o ta l tr i t ia t e d  f lu n itr a z e p a m  a d d e d  (n M ),
S b - S p e c i f ic a l ly  b o u n d  tr it ia te d  f lu n itr a z e p a m .
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Figure 14 Saturation Curve.Post-central Cortex. 
Sb
0.0391
max.
0.0285
0.0211
0.0132
0.0089
0.00 6.6471.8600.00
St
st-Total tritiated flunitrazepam Added (nM).
sb-Specifically bound tritiated flunitrazepam.
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Table 17 Experimental Binding Assay.Post-central Cortex. 
(Rosenthal NSB Correction)
Point Sb St
1 0.0086 0.3364
2 0.0168 0.7381
3 0.0278 1.528
4 0.0443 3.144
5 0.0612 6.538
6 0.0694 13.616
S t-T o ta l tr it ia te d  f lu n it r a z e p a m  a d d e d  (n M ).
S b - S p e c i f ic a l ly  b o u n d  tr it ia te d  f lu n itr a z e p a m .
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Figure 15 Saturation Curve.Occipital Cortex. 
Sb
0 . 0 4 5 3
0 . 0 3 9 1
max.
0 . 0 2 8 5
0.0132
0 . 0 0 8 9
0 .00,0.00 6 . 6 4 70 . 8 9 5 1.860
St
st-Total tritiated flunitrazepam Added (nM).
sb-Specifically bound tritiated flunitrazepam.
Table 18 Experimental Binding Assay.Occipital Cortex.
(Rosenthal NSB Correction)
Point Sb St
1 0.0089 0.895
2 0.0132 1.860
3 0.0211 3.425
4 0.0285 6.647
5 0.0391 13.192
6 0.0453 24.995
S t-T o ta l tr it ia te d  f lu n itr a z e p a m  A d d e d  (n M ).
S b - S p e c i f ic a l ly  b o u n d  tr it ia te d  f lu n itr a z e p a m .
Figure 16 Saturation Curve.Hippocampus.
Sb
0 . 0 3 7 9
0 . 0 2 8 6
0 . 0 2 0 7  -
0 . 0 1 4 5  -
max.
0.100 -
0 . 0 0 6 1  •
00.0 0 .8 0 1 00 .4 2 2 S
s b - S p e c i f i c a l l y  b o u n d  tr i t ia t e d  f lu n i t a z e p a m .
s t - t o t a l  t r i t ia t e d  f lu n i t a z e p a m .
Table 19 Experimental Binding Assay.HIPPOCAMPUS.
(Rosenthal NSB Correction)
Point Sb St
1 0.0061 0.4228
2 0.100 0.8010
3 0.0145 1.5385
4 0.0207 3.198
5 0.0286 6.472
6 0.0379 12.867
S t-T o ta l tr it ia te d  f lu n itr a z e p a m  a d d e d  (n M ).
S b -S p e c i f ic a l ly  b o u n d  tr it ia te d  f lu n itr a z e p a m .
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Figure 17 Saturation Curve.Cerebellum Cortex. 
Sb
0.1399
0.100
max.
0.939
0.0616
0.0*117
0.00
1 1 . 2 52.8640.00
st-Total tritiated flunitrazepam Added (nM).
sb-Specifically bound tritiated flunitrazepam.
Table 20 Experimental Binding Assay.Cerebellum Cortex.
(Rosenthal NSB Correction)
Point Sb St
1 0.0273 0.347
2 0.0417 0.694
3 0.0616 1.397
4 0.939 2.864
5 0.100 5.630
6 0.1399 11.246
S t-T o ta l tr it ia te d  f lu n itr a z e p a m  a d d e d  (n M ).
S b - S p e c i f ic a l ly  b o u n d  tr it ia te d  f lu n itr a z e p a m .
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Figure 18 Saturation Curve.Temporal Cortex. 
Sb
0.0358
0.0301
max.
0.0211
0.0138
0.0089
0.0051
6.2003.0810.0
0.0
st-Total tritiated flunitrazepam Added (nM).
sb-Specifically bound tritiated flunitrazepam.
Table 21 Experimental Binding Assay.Temporal Cortex.
(Rosenthal NSB Correction)
Point Sb St
1 0.0051 0.359
2 0.0089 0.726
3 0.0138 1.430
4 0.0211 3.081
5 0.0301 6.200
6 0.0358 13.713
S t-T o ta l tr it ia te d  f lu n itr a z e p a m  A d d e d  (n M ).
S b -S p e c i f ic a l ly  b o u n d  tr it ia te d  f lu n itr a z e p a m .
4.7 INFLUENCE OF AGE. SEX. CAUSES OF DEATH AND 
TIME INTERVAL BETWEEN DEATH AND AUTOPSY
4.7.1 INTRODUCTION
Estimation of the characteristics of membrane binding sites in the 
human brain post-mortem contributes to the understanding of the 
pathophysiology of diseases of the central nervous system and may suggest 
new therapeutic strategies. Alterations in neurotransmitter receptors have 
been described in post-mortem human brain in a wide variety of 
neurodegenerative disorders including Parkinson's disease (Olsen et al, 
1980), Huntington's disease (Whitehouse et al, 1985), Alzheimer's disease 
(Hardy et al, 1985) and in psychiatric disorders such as schizophrenia 
(Owen et al, 1978, Seeman, 1984) and depression (Meyerson et al, 1982, 
Stanley et al, 1982 and Perry et al, 1983). Interpretation of binding data is 
problematic, however, due to the rather small variations observed in 
pathological brains compared to controls, and factors which may affect the 
characteristics of binding sites must be excluded before the changes in 
receptor density and/or affinity observed in human brain post-mortem can 
be attributed to the pathological process.
The present study is concerned with the effects of factors such as 
age, sex, causes of death and post-mortem conditions (delay time interval 
between death and autopsy) that might affect the receptor molecules (Perry 
and Perry, 1983).
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4.7.2 REMOVAL OF BRAIN
Thirty-six human post-mortem brain tissue samples were removed as 
described in (4.5.3) and dissected rapidly. The frontal cortex tissue (grey 
matter) were collected from these samples under sterile conditions (white 
matter was avoided). All were shown to be free of benzodiazepine drugs by 
analysis of their blood samples using HPLC and radio-immunoassay.
One gram of human brain tissue (frontal cortex) was homogenized in 10 
ml of ice cold 0.32M sucrose solution using 20 strokes of Teflon-glass- 
homogeniser. The homogenate was centrifuged at 3500 rpm for 10 minutes at 
4 °C. The supernatant was centrifuged again at 15000 at 4 °C. The resultant 
pellet (crude P2 fractions) was suspended in 10 ml assay buffer (25 mM 
dihydrogenorthophosphate buffer pH 7.4). The membranes were frozen until 
used.
4.7.3 PREPARATION OF SYNAPTOSOMAL MEMBRANES
4.7.4 PROTEIN DETERMINATION
Protein concentration in each gram of human frontal cortex was 
determined by the method of Lowery et al as described in 4.4 using bovine 
serum albumin as standard.
4.7.5 BUFFER AND STANDARD PREPARATION
Buffer and standard preparation was carried out as described in 4.5.2.
4.7.6 BINDING STUDY
The maximum specific binding site concentration (using saturation 
curve analysis) was determined in all 36 of the human brain tissue samples 
(frontal cortex). The method used in this study has been modified from 
Horton et al (1982,1988).
Total Binding Assay
Total Binding Assay was determined as described in 4.5.5.
Non-Specific Binding
Non-specific binding was determined as described in 4.5.5.
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4.7.7 RESULTS AND DISCUSSION
The benzodiazepine receptor concentration in the frontal cortices was 
determined for 36 post-mortem cases all of whose blood samples had been 
tested for and found to be negative. Table 22 summarizes the 
characteristics of these cases with respect to age group (<40 years, 40-60 
years and >60 years). The number of benzodiazepine receptors in the 
frontal cortex was measured (using Saturation Curve) as 1305 + 92 (male), 
1268 + 30.7 (female) for age group one. For group 2 (40-60) this was 1267 + 
90 (male), 1250 ± 6 .1  (female) and for group 3 (>60) the number of 
benzodiazepine receptors in frontal cortex was 1166 + 90 (male), 1268 ± 47 
(female).
This study reveals no significant statistical variations in cortical 
synaptosomal binding in all three groups of age and these results are in 
agreement with the reports of Pedigo et al, 1981 and Tsang et al., 1982, on 
experimental animals. However, conflicting data have been claimed age- 
related changes: an increase (hippocampus only) (Memo et al., 1981) and a 
decrease (hippocampus and cortex) (DeBlasi et al, 1982) in cortical 
synaptosomal binding have been found for rats of different strains (Fischer 
344 or Sprague-Dawery). Although a final interpretation of this data is 
difficult due to many factors which might be responsible for alterations 
such as cell membranes, nuclei, chromatin, cyclic nucleotide metabolism 
and various cellular enzyme systems.
Several studies have reported age-related changes in receptor 
binding within the central nervous system. There are for example, papers
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describing decreased (Thai et al., 1980, Severson and Finch, 1980, Misra et 
al., 1980 and Memo et al., 1980) or increased (Marquis and Pelham, 1981) 
dopamine (DA) antagonist receptors, decreased p noradrenergic receptors 
(Misra et al, 1980, Greenberg and Weiss, 1978, Maggi et al 1979) decreased 
alpha receptors (Misra, 1980), unchanged (Memo et al, 1980, Pediog et al, 
1981, Heusner and Bosmann 1981) or increased (Memo et al., 1981, Reeves 
and Schweizer 1983, Dr Blasi et al 1982) benzodiazepine receptors, 
unchanged (Maggi et al., 1979) or decreased (Calderini et al., 1981) gamma- 
aminobutyric acid (GABA) receptors with aging. Unfortunately each 
receptor type was investigated separately and the differences in species, 
strains and age of the animals used by these authors make it difficult to 
assess whether age-related changes in receptor binding are a general 
phenomenon or whether some classes (or subclasses) of brain receptors are 
more affected than others by aging.
Most of the studies reviewed have focussed on changes in the 
density of the benzodiazepine receptor in animals. In humans more 
studies are urgently needed to ascertain parameters which effect the 
changes in the density of benzodiazepine receptors and to divide the data 
into genetically determined and presumably pathologically determined 
alteration, as was done for animal data.
Tables 23-26 list the binding site concentrations measured for 
36 brains from patients who had not received benzodiazepine drugs before 
death in males and females with respect to causes of death and the time 
interval between death and autopsy.
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With respect to the delay between time of death and post-mortem, 
the results show no significant effect. This is possibly due to storage of 
bodies in a refrigerator prior to autopsy. Also, the cause of death shows no 
significant change in the receptor density.
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Table 22: Binding site concentration of benzodiazepine receptors 
in the human frontal cortex area against sex and age 
group.
Binding site concentration (fmol/mg protein)
Age group Case No. Male Female
n l 1328 1281
n2 1375 X 1305 1250 X 1268
<40 n3 1270 SD 92 1305 SD 30.7
years n4 1210 cv7% 1220 cv 2.4%
n5 1230 1290
n6 1217 1260
n l 1272 1215
n2 1157 X 1267 1210 X 1250
40-60 n3 1212 SD 90 1320 SD 6.1
years n4 1193 cv7% 1185 cv 4.9%
n5 1230 1236
n6 1290 1333
n l 1275 1212
n2 1113 X 1166 1216 X 1209
>60 n3 1168 SD 90 1300 SD 47
years n4 1172 cv 4.5% 1180 cv 3.9%
n5 1232 1190
n6 1208 1157
-105-
Table 23 Effects of age cause of death on binding site
concentration in females.
Case No. Age Cause of death Binding site 
concentration
1 18 Chest&Abdominal
injuries(RTA)
1220
2 31 Myocarditis. 1305
3 33 Phenobarbitone Intoxication 1260
4 36 Acute Alcohol 
Intoxication(RTA).
1250
5 37 Spontaneous subarachnoid 
haemorrhage due to rupture of 
cerebral arteiy aneurysm
1290
6 38 Acute peritonitis due to 
chronic pancreatitis.
1281
7 46 Myocardial infarction. 1333
8 47 Scalding due to hot water. 1215
9 47 Coronary thrombosis 1185
10 48 Acute myocardial infarction. 1236
11 53 Ischaemic heart disease. 1320
12 59 Hypertension & Ischaemic 
heart disease.
1216
13 62 Ischaemic heart disease 1210
14 68 Lobar pneumonia 1190
15 68 Acute myocardial infarction 1330
16 68 Haemopericardium due to 
myocardial infarction
1157
17 78 Ischaemic heart disease 
coronary artery atheroma.
1212
18 85 Metastatic large bowel 
carcinoma&pulmonary 
thromb oemb olism.
1180
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Table 24 Effects of time interval (death&autopsy) on 
binding site concentration in females.
Case No. Age Time interval (death&autopsy) Binding site 
concentration
1 46 12 hours 1333
2 62 12 hours 1210
3 53 14 hours 1320
4 68 17 hours 1330
5 68 19 hours 1190
6 85 24 hours 1181
7 31 24 hours 1305
8 18 34 hours 1220
9 33 34 hours 1260
10 38 34 hours 1281
11 47 52 hours 1185
12 37 54 hours 1290
13 78 73 hours 1212
14 47 74 hours 1215
15 48 76 hours 1236
16 59 80 hours 1216
17 36 86 hours 1250
18 68 88 hours 1157
Table 25 Effects of time interval (death&autopsy) on binding site
concentration in males.
Case No. Age Time interval (death&autopsy) Binding site 
concentration
1 49 18 hours 1272
2 68 23 hours 1168
3 19 30 hours 1341
4 64 36 hours 1263
5 58 38 hours 1157
6 48 49 hours 1272
7 19 72 hours 1362
8 55 72 hours 1325
9 76 72 hours 1136
10 38 82 hours 1126
11 37 84 hours 1300
12 74 84 hours 1113
13 75 84 hours 1194
14 37 86 hours 1375
15 73 95 hours 1119
16 37 97 hours 1328
17 46 102 hours 1273
18 48 141 hours 1121
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Table 26 Effects of age and cause of death on binding
site concentration in males.
Case No. Age Cause Of death. Binding site 
concentration
1 19 Multiple injuries,Road traffic 
accident.
1341
2 19 Acute alcohol intoxication. 1362
3 37 Acute pancreatitis. 1300
4 37 Coronary artery atheroma. 1328
5 37 Chest&abdominal injuries,Road 
traffic accident
1375
6 38 Hanging. 1126
7 46 Cerebral abscess. 1223
8 48 Hanging. 1272
9 48 Acute artery atheroma. 1121
10 49 Acute myocardial infarction. 1272
11 55 Coronary artery 
atheroma,Bronchitis&emphysema
1325
12 58 Choking. 1157
13 64 Acute myocardial infarction. 1263
14 68 Ischaemic heart disease. 1168
15 73 Ruptured aortic aneurysm. 1119
16 74 Pulmonary thrombeoembolism. 1113
17 75 Acute bronchopneumonia. 1194
18 76 Haemopericardium due to 
myocardial infarction.
1136
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4.8 THE EFFECT OF BENZODIAZEPINE DRUGS
4.8.1 INTRODUCTION
The toxicological investigation of death by poisoning relies primarily 
on the analysis of a biological sample (blood, urine, liver, etc.) for the 
presence of a suspected drug. As a result, a level can be measured which 
can be compared with findings from previous cases. The finding will lie 
within the fatal, toxic, therapeutic, or sub-therapeutic range. Increased 
sophistication in this interpretation has been reported at international 
conferences where reported use has been made of the comparison of drug 
levels measured in samples taken from different sites in the body. This 
research presents the results of a preliminary investigation of the potential 
use of drug receptors as a means of diagnosing death by poisoning.
4.8.2 BRAIN SAMPLES
Six human post-mortem brain tissue samples (frontal cortex area, 
white matter was avoided) were gathered at autopsy as described in (4.5.3), 
from deaths due to various causes (males and females). Post-mortem blood 
samples were obtained under sterile conditions and examined for the 
presence of benzodiazepine drugs using HPLC and radio-immunoassay as 
detailed in Table 28.
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4.8.3 PREPARATION OF SYNAPTOSOMAL MEMBRANES
One gram of human brain tissue sample (frontal cortex) was 
homogenized in 10 ml of ice cold 0.32 M sucrose solution using 20 strokes 
of a Teflon homogeniser. The homogenate was centrifuged at 3500 rpm for 
10 minutes at 4°C. The supernatant was centrifuged again at 15000 rpm at 
4°C. The resultant pellet (crude P2 fraction) was suspended in 10 ml assay 
buffer (25 mm sodium dihydrogen orthophosphate buffer pH 7.4). The 
membranes were frozen until use.
4.8.4 BUFFER. LIGAND AND COLD LIGAND PREPARATION
Buffer, ligand and cold ligand preparation were carried out as 
described in 4.5.2.
4.8.5 PROTEIN DETERMINATION
Protein concentration in each gram of human brain tissues (frontal 
cortex) was determined by the colorimetric method of Lowery as described 
in 4.4.
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4.8.6 BINDING STUDY
The receptor binding assay used, has been modified from Horton et al. 
(1982, 1988) in order to determine the number of receptors available for 
binding in a preparation of brain tissue (frontal cortex).
Total Binding
Total binding was determined as described in 4.5.5.
Non-Specific Binding
Non-specific binding was determined as described in 4.5.5.
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4.8.7 RESULTS AND DISCUSSION
Table 28 and the saturation curve (Figure 19) from the data in 
Table 27, demonstrates a significant drop in frontal cortex benzodiazepine 
site concentrations in subjects who have been shown to have taken 
benzodiazepine drugs before death compared to the control group 
(Table 22).
Several studies have addressed the effects of chronic treatment with 
benzodiazepine drugs on animal receptor binding sites (rats, mice, etc.), 
with conflicting results. Roseborg and Chiu revealed a reduced number of 
benzodiazepine receptors in rat brain tissue (Chiu and Rosenberg 1978: 
Rosenberg and Chiu 1981) while employing receptor autoradiography for 
identifying rats' brain receptors Tietz et al. (1986) and by various 
investigators using low doses of have shown some reduction in receptor 
numbers in the brain tissues of mice and rats’ (Crawley et al 1982; 
Abbracchiu et al., 1983; Szcazwinska et al 1988, 1988). In addition, Miller 
and Co-workers, using a low dose of lorazepam and using in vivo binding 
to investigate receptor characteristics, have shown down-regulation of the 
benzodiazepine receptor in the brain tissue of mice (Miller et al., 1988a), 
and up-regulation on withdrawal (Miller et al., 1988 b). Grimm and 
Hershkowitz (1981) disclosed reduced benzodiazepine receptor numbers in 
the cortex and hippocampus of rats treated with low doses of diazepam for 
two weeks after they had been sacrificed two days after dosing. Some 
investigators have claimed no change in the benzodiazepine receptor 
densities in the brain tissues of rats and mice (Mohler et al., 1978; Rauch
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and Gallager, 1983; Stephens and Schneider, 1985; Heninger and Gallager, 
1988, Brett, 1992).
Other researchers have indicated receptor upregulation after chronic 
treatment. In a study on rat brain tissue Scharf and Feil (1983) revealed an 
increase in Bmax 18-25 hours after the last dose of a one week's treatment 
regime with clonazepam and lorazepam. A similar study on rat brain 
tissues by DiStefano et al. (1979) found a decrease in benzodiazepine 
binding 24 hours after cessation of 35 days of exposure to high-doses of 
diazepam, but an increase in binding 72 hours after the last dose. A similar 
result was outlined by Rogo et al. (1984), after 10 days of diazepam 
treatment.
The above conflicting data from animal research may be due to non­
comparable studies. The benzodiazepine dose, length of treatment, length 
of withdrawal period before sacrifice of the animal and method of tissue 
preparation vary. It has been shown that the duration of action, dose and 
treatment length are important to correlate any biochemical changes with 
observed behavioural changes (Brett, 1992). Finally, variations may be due 
to differences in species, in the absence of systemic or brain concentrations 
of drug, assay conditions and removal of endogenous GABA.
This study has dealt with human samples (brain and blood). The 
binding studies were performed in the presence of benzodiazepine drugs 
and were related and compared to a control group (Table 22). Blood and 
brain tissue benzodiazepine drug concentration (5.2.2.3.A and 5.2.2.3.B.) 
were measured. These measurements show that in the presence of
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benzodiazepine drugs at death there is an apparent decrease in the number 
of binding sites. The decrease in maximum binding was a specific 
response to prolonged occupation of binding sites. This specific adaptation 
to prolonged drug action favours the idea that the high-affinity binding 
sites represent a site of action of benzodiazepines.
4.8.8 CONCLUSION
In the presence of benzodiazepine drugs there is a decrease in number 
of benzodiazepine binding receptors in frontal cortex.
-115-
Figure 19 Saturation Curve.Pre-central Cortex.
St
St-Total tritiated fhmitrazepam.
Sb-Specifically bound tritiated flunitrazepam.
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Table 27 Experimental Binding Assay.Frontal Cortex. 
(Rosenthal NSB Correction)
Point Sb St
1 0.00800 0.3458
2 0.0159 0.6820
3 0.0228 1.3575
4 0.379 2.6052
5 0.0558 5.3227
6 0.0655 10.517
St-Total tritiated flunitrazepam added (nM). 
Sb-Specifically bound tritiated flunitrazepam.
Table 28 Changes in the density of the benzodiazepine receptors 
in the post-mortem brain samples of patients on 
benzodiazepine treatment.
Case
No
Age
(years)
Sex
Binding site 
concentration 
(fmol/mg protein)
Blood sample analysis 
(HPLC & RIA)
1 26 male 833 Temazepam, D.M.D. & 
Diazepam.
2 33 male 772 Temazepam & Diazepam
3 58 female 610 Temazepam.
4 24 male 844 Temazepam, D.M.D. & 
Diazepam.
5 24 male 976 Triazolam, D.M.D. & 
Diazepam.
6 20 female 658 Temazepam, D.M.D. & 
Diazepam
D.M.D: Desmethyldiazpam.
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5. BENZODIAZEPINES -EXTRACTION AND ANALYSIS
5.1 CHROMATOGRAPHIC ANALYSIS
Chromatography has been classically defined as a separation 
technique which enables samples or chemical mixtures to be separated by 
differential migration of their constituents during passage through a 
chromatographic column. If the stationary phase is a solid support or a 
liquid-coated solid support and the mobile phase is a liquid, the technique 
is known as liquid chromatography. Depending on how the stationary 
phase is physically applied, there are various forms of liquid 
chromatography. If the stationary phase is applied as a layer, the 
technique is referred to as thin-layer chromatography. When the stationary 
phase is placed in a column, the chromatographic system is liquid column 
chromatography. In gas chromatography the stationary is a solid support 
or a liquid-coated solid support and the mobile phase is a gas. The 
separation process is governed by the distribution of substances between 
two phases: the mobile phase (moving phase, carrier or eluent) and
stationary phase (packing material). The longer this process is allowed to 
continue, the greater separation is achieved. After the sample has been 
carried by the moving phase through the chromatographic bed, the liquid 
that emerges from the column, the column effluent, is a composite of the 
sample (the eluate) and the mobile phase (the eluent) (Krestulovic and 
Brown, 1982, Lindsay, 1987). Ideally, the mixture (sample) is completely 
separated by the time the components reach the end of the column.
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The elution of the components from the column is detected 
electronically by a suitable detector, and signals are sent to a strip chart 
recorder which displays the chromatogram. This chromatogram consists of a 
series of peaks, each of which indicates the elution of a component and the 
amount of component present. The time of elution is used to identify the 
components of the mixture and is defined as the elution time or retention time 
for a particular component. The peaks of the chromatograms should be 
completely separated. The peak width at the base should be narrow, even at 
the end of the chromatogram.
5.1.1 HPLC
High performance liquid chromatography (HPLC) has developed 
dramatically over the last fifteen years and is now a highly acclaimed 
technique in almost all areas of analytical chemistry. Major advantages of 
HPLC are (Brown, 1973, Hadden et al, 1971, Kirkland, 1971):-
- operation at low temperatures minimizes chances for thermo­
decomposition
- applicable to non-volatile and/or polar compounds.
- capable of separating components of widely differing polarities.
When the retention behaviour of components in HPLC is compared 
with that in other chromatographic techniques, such as GLC and TLC, the
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following observations can be made:
In GLC retention behaviour is mainly determined by the stationary 
phase, as the mobile phase serves merely as a transport medium.
In TLC, the stationary phase, the mobile and the vapour phase all affect 
the retention behaviour, which is usually a mixture of adsorption and partition 
processes.
Therefore, changing one or more of the phases may result in large 
differences in retention behaviour.
In HPLC there are two active phases, the stationary phase and the 
mobile phase and here too, changing one or both of the phases may have a 
large impact on the retention behaviour. In addition, in normal phase 
HPLC, adsorption processes may be assumed to dominate the separation, 
whereas in reversed-phase HPLC, partition processes are more important.
These advantages seem to justify an important role for HPLC in 
systematic toxicological analysis, in which it is common practice to use 
several techniques and systems side-by-side to detect and identify 
potentially harmful substances.
In high performance liquid chromatography the separation process 
is governed by the distribution of substances between two phases:
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the mobile phase (moving phase, eluent, carrier) and the stationary 
phase (packing material).
The extent of the interaction that results between the solute 
molecules and the molecules of each phase is determined by properties of 
the solute molecules in a given environment.
The basic operating forces exerted on solutes can be due to polarity 
arising from permanent or induced electric fields (Van der Waals forces) 
which depend on the relative masses of the solute and solvent molecules. 
In all forms of chromatography, any variable that can influence the balance 
of intermolecular forces which are responsible for selective retardation of 
solute molecules will affect the separation.
Expressions for the resolution, column efficiency and capacity factors 
are calculated from the widths and retention characteristics of the eluting 
peaks, i.e. all derived from easily measured parameters taken from the 
chromatographic trace as capacity factor, selectivity, column efficiency.
a) Capacity factor or capacity ratio (retention factor) (Kj)
— *1 ” i-o
1 = " V Equation 1.
_  _  *2~ tp 
K2 '  to
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t = void volume or dead volume = solvent front = is the retention Lo
time of an unretained component tQ (e.g the distance measured 
from the injection point to the apex of peak tQ), 
ti = the retention time of compound 1 (e.g. the distance measured 
from the injection point to the apex of the peak t , 
t = the retention time of compound 2 (e.g. the distance measured 
from the injection point to the apex of peak t ,
optimum ^  values should lie in range 1 < ^  <10.
b) The separation or selectivity factor A
A measures the ability of a column to separate components 1 and 2 due
to different affinity and therefore retention.
K
A = —2 Equation 2.
ix1
column capacity factor of component 1 
K2: column capacity factor of component 2.
For separation to occur A must be greater than 1.
c) The column efficiency is measured by (H), the height equivalent to
theoretical plate (HEPT).
L
H = ~  Equation 3.N
L: column length.
N: theoretical plate and number.
Efficiency is a function of a column length among other parameters, 
and, for purpose of comparison, efficiency is commonly expressed in terms of 
height equivalent to a theoretical plate (HEPT).
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(d) Resolution (R) is the quantitative description of the separation obtained 
between two peaks. This term which is defined by the following relationship:
In the Equation 4, t2 and tT represent retention times of peaks 1 and 2, 
while Wj and W2 represent peak widths of peaks 1 and 2 respectively.
There are four principal mechanisms in liquid chromatography by 
which components of samples are selectively retained. These are the 
exploitation of differences in partition coefficients (liquid-liquid 
chromatography), adsorption effects on surfaces such as silica gel (liquid-solid 
chromatography), dissociation of weak or strong electrolytes (ion-exchange 
chromatography, or in molecular size or shape (steric exclusion 
chromatography).
5.1.2 H P L C  SYSTEM FOR BENZODIAZEPINE ANALYSIS
The method used for benzodiazepine drugs (triazolam, temazepam, 
desmethyldiazepam and diazepam) analysis was high performance liquid 
chromatography based on a Gilson 305 Pump with single piston rinsing head. 
The detector used was a variable wavelength ultraviolet detector (Gilson 115)
with an 8 ul flowcell with a path length 10 mm. The column was a 25 cm x 4.6 
mm I.D (Internal diameter) cartridge pre-packed with Hypersil 5 um ODS C|g 
(Capital HPLC specialists) fitted with 5 cm 4.6 mm I.D ODS C^g guard
column. The injector valve was a Rheodyne 7125 with 20 ul loop.
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Benzodiazepine drugs were monitored at 230 nm. The chromatograms were 
recorded on a BBC Goerz Metrawatt SE120 recorder, operated at 1 cm/min 
and at 10 mV full-scale deflection.
5.1.3 MOBILE PHASE
The mobile phase of 0.01M disodium hydrogen orthophosphate 
dihydrate (Na2HP04.2H20 M.wt 177.99) (pH8.8) and methanol in the
proportions (30:70 v/v) was used. The resulting mobile phase was degassed
with helium 10 minutes before use. Disodium hydrogen orthophosphate
dihydrate buffer of 0.01 M was prepared by dissolving 1.78 gram of 
Na2HP04.2H20 in deionised water and making up to one litre (Eppel, 1980).
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5.2 METHODS OF EXTRACTION
5.2.1 INTRODUCTION AND LITERATURE REVIEW
The principle behind the different extraction techniques available is 
basically the same - to retain the analyte(s) of interest and allow interfering 
compounds to be removed with an appropriate solvent, before quantitatively 
euluting the drug which can then be analysed by such methods as high- 
performance liquid chromatography (HPLC), gas chromatography (GC) or 
mass spectrometry (MS).
The phase which retains the analyte can be a water-immiscible solvent, 
e.g. ethyl acetate as in the popular liquid-liquid extraction (LLE), a solid phase 
such as XAD-2 a polystyrene medium capable of removing proteins, fats and 
lipids, on porous polymer beads or inorganic porous materials for the 
extraction of urine. The last group includes diatomaceous earths, magnesium 
silicate, alumina and charcoal but the most widely used sorbent is silica.
Liquid-liquid extraction remains the most commonly used sample 
preparation technique in analytical toxicology. Drugs are extracted from 
biological samples by partitioning between two immiscible solvents, often 
adjusting pH to control ionization. Back-extraction at a different pH often 
improves selectivity and recovery.
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The majority of methods used for extracting benzodiazepines from 
biological fluids have been based on partitioning of the drugs in favour of an 
organic solvent from a (usually alkaline) buffered aqueous solution.
Buffers have ranged in pH from that of physiological fluids (7.4) to 
about 10, while the choice of extracting solvent has involved n-hexane (light 
petroleum) (Verebey and Mule, 1982), toluene, (Lindley, 1979), (Wong, 1983), 
octanol, (Pegaon et al., 1982), chloroform (Curry, 1976, Slightom, 1982) diethyl 
ether (McCurdy et al, 1979; Martinez and Grimenez, 1981; Poklis, 1981), n- 
butyl chloride (Dickson et al. 1980; Peel and Perrigo, 1980), n-butylacetate 
(Osselton et al, 1980; Rutherford, 1977). Mixed solvents like chloroform-ether 
(Parry and Ferry 1976) or toluene-n-heptane-isoamyl alcohol (Peat and Kopjak, 
1979) have also been used. In an article by Clifford and Smyth over half of the 
extractions reviewed had been made using diethyl ether (Clifford and Smyth, 
1974).
The disadvantages of liquid-liquid extraction are the time required for 
multi-step extractions, the expense and disposal considerations for large 
volumes of organic solvents, and the limited precision resulting from non- 
selective extraction of other compounds that may interfere with analysis 
and/or cause variable recovery of the analyte (s). In addition, emulsions are 
often formed that may require additional steps to produce an adequate 
separation.
More recently, there have been various attempts to replace the time- 
consuming traditional solvent extraction procedures by liquid-solid solvent 
extraction. The principle of liquid-solid absorption extraction involves the
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absorption of the aqueous phase onto diatomaceous earths, a porous material 
which acts as a support for the aqueous phase. This provides a large surface 
area for partition into an eluting solvent, which flows though the immobilized 
specimen under gravity, eluting the analytes of interest. These materials are 
capable of being loaded to the limit of their water absorption capacity without 
releasing any of the water upon elution with solvents. The diatomaceous earth 
is inactive and chemically inert; the pH value of absorbed aqueous solutions 
can range between pHl and 13. It is possible therefore, to elute substances at 
an optimum pH to separate acidic, neutral and alkaline compounds. 
Biological samples such as urine, blood, serum, plasma, gastric juice, liquor, 
and tissue can be extracted by this type of material. Samples extracted 
through diatomaceous earth do not need any kind of special treatment, such as 
filtration or centrifugation, before applying the sample.
A method for benzodiazepine drugs extraction using diatomaceous 
earth has recently been reported (Logan and Stafford, 1989) with a recoveries 
of 70 ± 7.6% and 74 ± 9.5% for diazepam and alprazolam respectively. 
Lillsunde and Korte (1991) successfully extracted 12 benzodiazepine drugs 
from urine using diatomaceous earth (Chem-Elut) with recoveries in the range 
of 60-95% for oxazepam and chlordiazepoxide respectively. While Cordonnier 
et al. (1987) extracted some benzodiazepines from spiked human liver tissue 
with recoveries ranging from 69-83% with day to day variation ranging from 
3.7-8.7%. The disadvantages of using diatomaceous earth in extracting drugs 
from biological fluids is the large volume of solvent (10-20 ml) that must be 
evaporated before the next chromatographic step and identification can take 
place.
-128-
Another type of adsorbent is the cross-liked divinylbenzene- 
polystyrene resin XAD-2 (Bastos et al, 1972). Urine containing diazepam was 
extracted by Amberlite XAD-2 and diazepam eluted from the column with 4 x 
20 ml portions of methanol. The first 20 ml of the elution solvent (methanol) 
gave the highest recovery of 61.3 ± 1% and the lowest was in the fourth 20 ml 
of the elution solvent with recoveries of 5.7 + 1.2% (Hyde, 1985). The total 
recovery was 96.2 + 0.4%. The limitations of using XAD-2 for extracting 
compounds from biological material are the need for large volumes of elution 
solvents, usually organic solvents and (Hyde, 1985) the lengthy conditioning 
prior to use. Also they swell unpredictably in response to organic solvent 
(Harkey and Stolowitz, 1984).
5.2.2 SOLID PHASE SORBENT
The use of chemically bonded silicas for sample preparation followed 
their use in high performance liquid chromatography (HPLC) to provide a 
selective separation of compounds. These materials usually provide a better 
recovery of drugs from biological matrices and may be more convenient than 
other procedures used in analytical toxicology (Stewart et al 1984, Hyde 1985).
Bonded silicas are packed either in individual cartridges that can be 
attached to a syringe or in syringe barrels, as showed in Figure 20. The barrel 
is made from medical grade polypropylene with the bonded material held in 
place between two polyethylene fritted disks.
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Figure 20 Sorbent Extraction Cartridge.
—> reservoir
—> upper frit
—> sorbent.
—> lower frit.
—> luer tip
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Solid Phase Sorbent Properties
Bonded silicas are formed by reaction of organosilanes with activated 
silica. The product is a sorbent with the functional group of the organosilane 
attached to the silica substrate through a silyl ether linkage. The product is 
stable within a pH range of approximately 2-7.5. Above pH 7.5 the silica 
substrate is susceptible to dissolution in aqueous solutions. Below pH 2.0 the 
silyl ether linkage is labile and the functional groups on the surface will begin 
to cleave. In practice bonded silicas may be used for sorbent extractions in the 
pH range 1-14 since degradation of the sorbent is a finite process and sorbents 
are typically exposed to solvents for only short periods of time. Bonded silica 
sorbents are rigid materials that do not shrink or swell in different solvents, 
unlike many polystyrene-based resins. For this reason, bonded silicas 
equilibrate rapidly to new solvent conditions. This allows complex extraction 
procedures involving many different solvent changes to be performed rapidly.
Sorbent extraction is a physical extraction process that involves a liquid 
and a solid phase. In sorbent extraction the solid phase has a greater attraction 
for the isolate than the solvent in which the isolate is dissolved. As the sample 
solution passes through the sorbent bed, the isolate concentrates on this 
surface, while the other sample components pass through the bed. Very 
selective extractions resulting in highly purified and concentrated isolates can 
be achieved by choosing sorbents with an attraction for the isolate but not for 
the other sample components.
A silica sorbent resembles a forest of functional groups anchored 
through a root system of siloxane bridges. These bonds and the silica beneath
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them are responsible for two important properties of silica sorbents: the need 
for solvation of the materials and the potential for secondary interactions with 
isolate molecules. Therefore solvation of a sorbent is necessary before the 
sorbent will interact reproducibly with the isolate. Solvation is a wetting of 
the sorbent creating an environment suitable to the isolate the drug. Retention 
is accomplished by passing several bed volumes of a suitable solvent. The 
adsorptive properties of a bonded silica are due principally to the functional 
groups bonded to the silica substrate. Any unbonded silanols remaining on 
the surface are a contributory factor to retention. Interaction between the 
substrate and isolate molecules is called a secondary interaction. It may be the 
predominantly active property of a sorbent. As a particular sample is passed 
through a sorbent bed, compounds present in the sample will either pass 
through the sorbent or be retained on the sorbent due to an attraction that 
exists between the sorbent and the isolate molecules, causing the isolate to be 
immobilized; this phenomenon is called retention. The process by which an 
isolate is removed from a sorbent bed in which it has been retained is called 
elution.
The selectivity of the sorbent is the ability of the sorbent to discriminate 
between the isolate and all other matrix components. It is a function of three 
parameters: the chemical structure of the isolate, the properties of the sorbent 
and the composition of the sample matrix.
The capacity of a given sorbent is defined as the total mass of a strongly 
retained isolate that can be retained by a given mass of the sorbent under 
optimum conditions. Capacity values range from less than 1% to 5% of
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sorbent mass that is, 100 mg of sorbent might retain as much as 5 mg of a 
strongly retained isolate (Home, 1985).
5.2.2.1 THE CHOICE OF BONDED PHASE
The choice of bonded phase depends on the sample matrix. For
aqueous samples such as serum or urine, non-polar extraction is often used
because non-polar drugs are easily extracted from an aqueous sample onto a
non-polar phase and recovery depends less on pH and salt concentrations. To
improve the selectivity of extraction, polar or weak ion exchange phases may
be used; however, these phases often require sample pretreatment (e.g.
sample dilution or pH adjustment) to efficiently extract a drug from the
sample matrix. The lipid solubility and polar characteristics of the drug
should first be considered. If the drug is very hydrophobic, the initial trial 
should include C2 and Cg phases, as well as C^g for comparison.
Alternatively, if the drug has polar substituents, a cyano and/or diol phase 
may be more selective than Cg or Cjg columns.
After conditioning the bonded phase, the sample is added (usually 0.1- 
1 ml). Serum or plasma samples are usually added directly, but urine may be 
diluted with water or buffer to improve extraction from very concentrated 
samples. When extracting whole blood, the haemolysed sample is filtered or 
centrifuged to remove cellular debris that can clog the frits in the extraction 
column or physically interfere with extraction (Harkey, 1989). As the sample 
passes through the extraction column, components will either bind to the 
bonded phase or pass through the column unretained, depending on the
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affinity of the compound for the bonded phase as compared to its solubility in 
the sample matrix.
After the sample is extracted potential interferences may be removed by 
washing the column. For most non-polar phases, water can be used to remove 
many of the polar constituents of serum or urine without eluting drugs. More 
non-polar contaminants may be removed by adding relatively weak solutions 
of methanol or acetonitrile in water or buffer.
Finally, the analyte is eluted from the extraction column. The elution 
solvent for non-polar phases is usually methanol, acetonitrile, or a mixture of 
organic solvent with water or buffer. Depending on the concentration of the 
analyte and the method of analysis, this solution may be analysed directly 
without evaporation and reconstitution. To improve sensitivity the analyte 
should be eluted in as small a volume as possible, which typically concentrates 
the samples five to tenfold. However, the volume of eluting solvent must be 
sufficient to pass through all pores and interstitial spaces in the bonded phase.
Large numbers of publications in recent years have reported the use of
bonded silica for benzodiazepine drugs extraction from serum, plasma and 
urine using Cjg columns (Wilhelm and Kemper, 1990; Suzuki et al, 1988;
Kabra and Uche Nzekwe, 1985; Seno et al, 1991; Carlucd, 1988; Good and 
Andrews, 1981; Stewart et al, 1984; Rao et al, 1982). Moore and Oliver, 1988 
and 1992 - used other commercially bonded phase columns (Cg and -CN
columns) to extract benzodiazepine drugs from greyhound urine. Recoveries 
in excess of 85% for Cg columns and above 90%, for nineteen benzodiazepine
drugs extracted from CN columns were reported. More selective sorbents
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such as ion exchange is (SCX) have been used for the extraction of the 
benzodiazepines and drugs from human urine (Logan et al 1990). This 
workers recorded with absolute recoveries ranging from 78 + 5.5 to 95.0 ± 6.4 
for diazepam and nordiazepam respectively.
The above-reported benzodiazepine drugs extraction procedure is not 
applicable to whole post-mortem human blood or tissue samples. Since most 
of the post-mortem blood which is routinely encountered in forensic 
toxicology casework is usually haemolysed and often putrefied.
Seno et al (1991) claimed a good recovery but, unfortunately, this paper 
gave no recovery data for the twelve benzodiazepines extracted from urine, 
plasma and whole blood. His method was based on converting the 
benzodiazepines to benzophenones. This method of extraction required 
sample preparation including treating the biological materials with 
hydrochloric acid and heating at 100°C for one hour in the case of urine or 
centrifugation at 35000 rpm for 5 minutes in the case of serum and whole 
blood. This makes this method time-consuming. Also, the GC chromatograms 
showed big impurity peaks, which could be due to using a non-selective solid 
phase sorbent (Cqg).
A literature review provided no reports on direct extraction of 
benzodiazepines from human post-mortem blood employing solid phase 
sorbent systems. A method has been developed to extract benzodiazepines 
from human post-mortem blood directly and with special sample treatment in 
the case of human brain tissue extraction.
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Solid phase extraction techniques are gaining a wider acceptance as 
sample clean-up tools in pharmaceutical analysis especially for drugs in 
biological material.
Four commercially available solid adsorbent materials were evaluated 
for their applicability as tools for the extraction of five selected benzodiazepine 
drugs from aqueous, post-mortem human blood and human brain tissue 
samples. Five benzodiazepine drugs were selected.
5.2.2.2 POLAR INTERACTION (NH2/CN)
Polar interactions are exhibited by many different sorbents and 
functional groups on isolates. Polar interactions include hydrogen bonding, 
dipole/dipole induced dipole/dipole, Pi-Pi, and a variety of other interactions 
in which the distribution of electrons between individual atoms in the 
functional groups is unequal, causing positive and negative polarity. This 
property allows an isolate molecule bearing a polar functional group to 
interact with a polar group on a sorbent. Groups that exhibit these types of 
interactions typically include hydroxyls, amines, carbonyls, aromatic rings, 
sulphydryls, double bonds and groups containing hetero-atoms such as 
oxygen, nitrogen, sulphur, and phosphorus.
Because of the polar nature of the silica substrate (and especially of 
unbonded silanol groups), polar interactions are characteristic of all bonded 
silicas. These secondary polar interactions of the silica are most significant in
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non-polar solvents. Amine and hydroxy isolate groups are the most sensitive 
to polar secondary interactions.
Hydrogen bonding is one of the more significant polar interactions. It 
occurs between one group that contains hydrogen bonded to an electro­
negative atom such as oxygen or nitrogen, and another group bearing an 
electro-negative atom. Hydroxyl groups and amines are the most common 
hydrogen bond donors. Functional groups that can interact with hydrogen 
bond donors (i.e., hydrogen bond acceptors) are other groups containing 
oxygen, nitrogen, or sulphur atoms.
Polar interactions between polar sorbent groups and polar groups on 
isolates are facilitated by non-polar solvents. This is because the strong 
electronic interaction between the sorbent and the isolate cannot be easily 
disrupted by non-polar solvent molecules. Conversely, polar interactions are 
most effectively disrupted by polar solvents, because polar isolates are more 
soluble in polar solvents, and because polar solvents can compete more 
effectively with the isolate for the sorbent than can non-polar solvents.
High ionic strength also will disrupt polar interactions. Often, polar 
isolates will be retained on non-polar sorbents through secondary interactions 
with the silica substrate, but this retention is inhibited by high ionic strength.
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NHo (AMINOPROPYL) SORBENTS
The NH2 functional group is capable of exhibiting all possible
interactions. For this reason, it is important to pay close attention to the
solvent/sample matrix environment, which will dictate the interactions 
occurring. An NH2 group imparts polar properties to a sorbent, and strong
hydrogen bonder that also can function as an anion-exchanger. Since the pKa 
of the NH2 sorbent is 9.8, at any pH below 9.8 NH2 is positively charged.
It is a weaker anion-exchanger than sorbents like SAX (a quaternary 
amine sorbent that is always charged), and is therefore a better sorbent choice 
for retention of very strong anions, such as sulphonic acids which may be 
retained irreversibly on SAX.
Although NH2 has been used for non-polar isolations from polar 
solvents, its extreme polarity makes its non-polar character less significant 
than its other properties.
CN (CYANOPROPYL) SORBENTS
A medium polarity sorbent, CN is ideal for applications in which 
extremely non-polar isolates would be irreversibly retained on non-polar 
sorbents such as Cjg or Cg. Conversely, CN can be used as a polar sorbent
that is less retentive for very polar isolates that might be retained irreversibly 
on the more polar sorbents, such as silica or diol. The cyano group provides a
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unique selectivity, which can be moderated by intelligent use of eluting 
solvents.
I. Extraction Buffer Preparation
Disodium hydrogen orthophosphate dihydrate (Sorensen's Salt, 
Na2HP04.2H20, m.wt 177.99) buffer was made up by dissolving 1.78 grams of 
Na2HP04<2H20 in deionised water and making up to one litre. The resulting
buffer concentration of 0.01M was adjusted with a few drops of 
orthophosphoric acid (H3PO4) to pH 7.
II. Standard and Internal Standard Solutions
A stock solution containing the four benzodiazepine drugs (triazolam, 
temazepam, desmethyldiazepam and diazepam) was prepared by dissolving 
2 mg of each drug in a few drops of methanol and then diluting to 100 ml with 
deionised water to produce a stock standard solution of 20 ug/ml. Further 
dilution with deionised water was made to produce a working solution of 
9 ug/ml.
The internal standard solution (prazepam) was prepared by dissolving 
2 mg in a few drops of HPLC grade methanol and making up to 100 ml with 
deionised water, the resulting concentration being 20 ug/ml.
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III. Sample Preparation
0.9.ml of deionised water was transferred to a 6 ml screw-capped vial. 
The following solutions were added:
1. 0.1 ml of the working standard mixture of benzodiazepine drugs 
(9 ug/ml).
2. 0.1 ml internal standard (prazepam 20 ug/ml).
3. 1 ml of 0.01M disodium hydrogen orthophosphate buffer (pH 7).
The vial was mixed well and the samples were extracted as follows:
IV. Extraction Procedure
CN (cyanopropyl) is a medium polarity sorbent, while NH2 
(Aminopropyl) is a very polar sorbent and a strong hydrogen bonder.
Bond ElutR (CN, NH2) columns of 3ml capacity were used. They were
conditioned with 3 x 1ml of methanol followed by 3 x 1ml deionised water 
and followed by 3 x 1ml (0.01M, pH 7) disodium hydrogen orthophosphate 
dihydrate buffer.
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V. Addition of Sample
The above mixture (ID above) was transferred to pre-conditioned Bond 
ElutR CN, NH2 columns and drawn slowly through under vacuum. The
vacuum pressure generated by the water pump was kept between 5-10 PS.I. 
The cartridge was not allowed to dry out.
The sorbent was washed twice with 1 x 1 ml 0.01M Na2H^04 (pH 7),
and drained by passing air for 30-40 seconds, the column was washed twice 
with 1 x 1ml of 0.01M Na2HP0 4  (pH 7).
VI Elution of the Sample
The drugs were eluted from the sorbents using different elution 
solvents:
a. 1% H3PO4 in methanol - the pH of the solution was adjusted to 
pH4 by adding a few drops of ammonia solution (NH3 35%).
b. Methanol was adjusted with a few drops of IN sodium 
hydroxide (NaOH) to pH 11.
VII. Analysis of the Sample
The eluent was evaporated to dryness by placing the vial on a hot plate 
at 60°C under a nitrogen gas stream. The extract was reconstituted in mobile 
phase (100 ul) (Section 5.1.3). 20 ul was injected onto the HPLC system.
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VIII. Results and Discussion
The relative recoveries of the four benzodiazepine drugs (triazolam,
temazepam, desmethyldiazepam and diazepam) from spiked deionised water 
using the two sorbents (CN = cyanopropyl and NH2 = aminopropyl) were
calculated by comparing the peak height ratio of the extracts from deionised 
water with un-extracted standard solutions prepared in mobile phase at the 
same concentration and under identical conditions.
Table 29 lists a recovery of above 88% for all benzodiazepine drugs 
using the acidic eluent and low recoveries using the basic eluent (less than 
76%).
Extracting whole post-mortem blood samples with four benzodiazepine 
drugs with Bond Elut CN columns, of 6ml capacity, using acidic elution. The 
extracts were susceptible to emulsion formation which account for the 
recovery and there was considerable sample to sample formation. Peaks were 
broad and badly tailed.
-142-
IX CONCLUSIONS
In order to improve the efficiency, selectivity and to avoid problems 
arising from polar sorbent, it was decided that further work should be done 
using other solvents and changes in columns.
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Table: 29 Percentage Recoveries of Benzodiazepine Drugs 
(0.9 ug/ml) from Spiked Water Using Polar Sorbents
CYNOPROPYL Triazolam Temazepam Desmethyl-Diazepam
D iazepam
Acidic eluent 97 ±3.1% 99 ±2.2% 90 ±3.8% 89 ±  5.2%
Basic eluent 54 ±2.8% 75 ±2.9% 76 ±  4.3% 81 ±  2%
AMINOPROPYL
Acidic eluent 25 ±3% 13 ±2% 19 ±6.1% 18 ±3%
Basic eluent 24 ±2.7% 8 ±6% 13 ±3.9% 15 ±6.2%
Column: Hypersil 5 um Q^g Universal Cartridge (25 cm x 4.6 mm i.d.)
Mobile Phase: 0.01M disodium hydrogen orthophosphate
(pH 8.8):Methanol (70:30)
Detection Wavelength: 230 nm 
Flow Rate: 1 ml/minute
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5.2.2.3 EXPLORING THE NON-POLAR INTERACTION (C2.C8)
Non-polar interactions are those that occur between the carbon- 
hydrogen bonds of the sorbent functional isolate. These forces are commonly 
known as "Van der Waals" or "dispersion" forces. Since most organic 
molecules have some non-polar structure, non-polar interactions are often 
used to retain isolates on sorbents offering non-polar functional groups on the 
surface.
Unbonded silica does not exhibit non-polar interactions. Since most 
sorbent functional groups are bonded to the silica substrate through carbon 
chains of some length, all of the other commonly available sorbents exhibit 
some degree of non-polar interactions.
All isolate species have a potential for non-polar interactions. 
Exceptions include inorganic ions and compounds (carbohydrates, for 
example) whose structure contains so many polar or ionic groups that the 
carbon structure of the molecule is masked.
Non-polar interactions between non-polar sorbents and non-polar 
isolates are facilitated by solvent environments that are very polar in nature. 
Polar solvent/matrix environments are generally not capable of disrupting the 
dispersion forces of the non-polar interaction. Even where the isolate has 
polar groups, any significantly non-polar part of the isolate will interact with 
non-polar functional groups of the sorbent in a polar environment. The best 
example of a solvent that facilitates retention due to non-polar interactions is 
water.
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On the other hand, non-polar interactions between the isolate and the 
sorbent are best disrupted by solvents having some degree of non-polar 
character. For many isolates, even a solvent as polar as methanol has enough 
non-polar character to disrupt the non-polar interaction between the isolate 
and the sorbent, causing elution of the isolate from the sorbent. For more non­
polar isolates, a solvent as non-polar as chloroform may be required for elution 
of the isolate.
£ 1S (QCTADECYL)
Cjg is the most non-polar sorbent available. It is the most retentive of 
all sorbents for isolates being retained by a non-polar mechanism.
Extremely non polar compounds are often difficult to elute from Cqg. 
C}g is generally regarded as the least selective sorbent, since it retains almost
everything from aqueous matrices - often a benefit when the isolates vary 
widely in structure. Because of Cjg's low selectivity, final extracts are often
not as pure as they are when more selective sorbents are employed. Cqg is 
excellent for desalting matrices prior to ion-exchange because salts pass 
through it unretained.
The potential for polar interactions between isolates and sorbent is less 
significant with Cjg than with any other sorbent because of the predominant
effect of the long hydrocarbon chain.
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C8 (OCTYL. 8-CARBON STRAIGHT-CHAIN HYDROCARBON)
Cg is very similar in properties to C^g, but not quite as retentive for 
non-polar isolates, due to its shorter hydrocarbon chain. For this reason, Cg is 
a good replacement for Cjg for isolates that are too strongly retained on Cjg 
for effective elution. Almost all other considerations are the same for C}g 
and Cg.
Non-polar isolate retention is facilitated on Cg by conditioning with 
organic buffers as opposed to inorganic. In general inorganic buffers at high 
ionic strenght will promote isolate elution.
The potential of Cg for polar interactions with isolates is somewhat 
higher than for Cjg because the shorter hydrocarbon chain does not mask the
silica surface as effectively, but polar interactions are still not a significant 
property of Cg.
C2 (ETHYL, 2-CARBON STRAlGHT-CHAIN HYDROCARBON!
Because of the very short chain length of the functional group, leaving 
the silica surface somewhat exposed, C2 is a fairly polar sorbent.
C2 is often used as a replacement for C^g and Cg when isolates are 
retained too strongly by the latter. C2's polarity is slightly greater than CN for 
polar interactions.
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A. HUMAN POST-MORTEM BLOOD
Authentic human post-mortem blood tested for the presence of 
benzodiazepine drugs and shown to be negative for all benzodiazepines 
(using HPLC and radio-immunoassay) was used to prepare a standard 
benzodiazepine drugs mixture (triazolam, temazepam, desmethyldiazepam 
and diazepam).
I. Extraction Buffer Preparation
Disodium hydrogen orthophosphate dihydrate (Sorensen's Salt 
Na2HP04.2H20, M.wt 177.99) buffer was made up by dissolving 1.78 grams of
Na2HP04.2H20 in deionised water, the resulting buffer concentration of 0.01M
was adjusted with a few millilitres of IN sodium hydroxide (NaOH) to 
pH10.4.
II. Stock Standard and Internal Standard Preparation
A stock solution containing the four benzodiazepine drugs (triazolam, 
temazepam, desmethyldiazepam and diazepam) was prepared by dissolving 
2 mg of each drug in a few drops of methanol and then diluting to 100 ml with 
deionised water to produce a stock standard benzodiazepine solution of 
20 ug/ml. Further dilution with deionised water was made to produce a 
working solution of 9 ug/ml.
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The internal standard solution (prazepam) was prepared by dissolving 
2 mg with a few drops of HPLC grade methanol and making up to 100 ml 
with deionised water, the resulting concentration of 20 ug/ml.
III. Sample Preparation
0.9.ml of blank human post-mortem blood was transferred to a 6 ml 
screw-capped vial. The following solutions were added:
1. 0.1 ml of the working standard mixture of benzodaizepine drugs
(9 ug/ml).
2. 0.1 ml internal standard (prazepam 20 ug/ml).
3. 1 ml of 0.01 M disodium hydrogen orthophosphate buffer
(pH 10.4).
4. 1 ml of 2% ammonia solution (NH3 35%)
Then the tube was mixed well. Six samples of spiked human post­
mortem blood were extracted through Bond ElutR Cg columns of 3 ml
capacity.
IV. Extraction Procedure
Bond ElutR C2 or Cg cartridges (3ml capacity) were attached to a Vac- 
Elut box, which can hold up to 10 cartridges. Vacuum was applied using a
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water pump and the cartridges were conditioned as follows by drawing the 
following solutions through in succession:
- 3ml x 1ml of HPLC grade methanol
- followed by 3 x 1ml deionised water
- followed by 3x lml  0.01M disodium dihydrogen ortho­
phosphate (pH 10.4).
V. Addition of Sample
The prepared sample was transferred to the preconditioned Bond ElutR 
C2 or Cg column with the aid of a disposable pipette and drawn through
under vacuum (the vacuum pressure generated by the water pump was kept
between 5-10 PSI and the cartridge was not allowed to dry out between
successive applications); then the column was washed twice with 1 ml of 
0.01M Na2HP04 (pH10.4) followed by 2 ml HPLC grade hexane.
VI. Elution of the Sample
The sorbent was washed twice with 2ml of 0.01M Na2HP04 (pH10.4) 
and final elution of the drugs from the sorbent was performed with 1 x 5ml 
chloroform.
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VII. Analysis of the Sample
The extract was evaporated to dryness by placing the vial on a hot plate 
60°C under a gentle stream of nitrogen gas. The residue was redissolved in 
mobile phase (0.1 ml Section 5.1.3.) and complete solution of the extract was 
achieved by placing in an ultrasonic bath for 5-10 minutes. 20 ul was injected 
onto the HPLC.
VIII Results and Discussion
Recoveries and Calibration Curves
The relative recoveries of the four benzodiazepines from spiked human 
post-mortem blood extracted using Bond ElutR Cg columns of 3 ml capacity,
containing Cg packing material was calculated by comparing the peak height
ratios of the extracted samples with un-extracted standards prepared in mobile 
phase at the same concentration (Tables 30-33).
The calibration curves for the four benzodiazepine drugs (triazolam, 
temazepam, desmethyldiazepam and diazepam) were constructed over the 
concentration range (0.05-2 ug/ml) prepared in blank human post-mortem 
blood. Six samples at each concentration for each drug were extracted through 
Bond ElutR Cg columns. The internal standard (prazepam) was added to all
samples. The peak height ratios of drug over internal standard at each 
concentration were plotted to construct a calibration curve for each 
benzodiazepine drug. The relation between benzodiazepine drugs (triazolam,
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temazepam, desmethyldiazepam and diazepam) concentration and average 
peak height ratio (std/I.S) of samples analysed by HPLC are highlighted in 
Tables 34-37. A standard calibration curve was constructed using the peak 
height ratios (std/I.S) and the benzodiazepine drug concentrations. A linear 
relation was obtained for each drug as shown in Figure 21-24. A 50 ng/m l of 
benzodiazepine drugs extracted solution was found to be easily detected at 
range 0.02, Figure 25.
From the results obtained above it can be seen that the method will 
detect 50 ng/ml of benzodiazepine, a typical chromatogram for this level is 
illustrated in Figure 25.
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The Reproducibility of theExtraction Method
30 samples of human post-mortem blood spiked with the four
benzodiazepine drugs mixture (triazolam, temazepam, desmethyldiazepam
and diazepam) in a concentration of 0.9 ug/m l of blood were extracted 
through Bond ElutR Cg column 3 ml capacity and analysed over three
successive days. The peak height ratio of each drug was used to calculate 
the within day and day to day variation of the extraction and analysis 
method of the four benzodiazepines using HPLC system.
Table 38 shows the average recoveries,coefficient of variation and 
number of samples used each time. Excellent recoveries were obtained for 
the four benzodiazepine drugs. The recovery was calculated by comparing 
the peak height of unextracted standard benzodiazepine drugs with 
extracted samples.
CONCLUSION
The developed method used gives rapid identification and 
quantitation of the four benzodiazepine drugs (triazolam, temazepam, 
desmethyldiazepam and diazepam) most often encountered in Forensic 
Toxicology Cases.
The developed procedure has the advantages of minimal handling 
time (the chromatographic run time was less than 14 minutes at a flow rate 
of lml/minute and no peaks eluted after the internal standard, Figure 25
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and Table 39), high recovery (even at subtherapeutic levels), and clean 
sample extracts. The method eliminates the need for expensive equipment 
such as centrifuges, shakers and glassware. A well-trained technician can 
obtain the results for twenty samples in less than six hours using the 
method outlined.
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TABT.E 30.
The recovery of triazolam from spiked post-mortem blood 
extracted through a Cg-column and analysed by HPLC.
Concentration
pg/ml
Recovery Number of samples
0.05 101±3.0% 6
0.2 102±4.0% 6
0.9 87±7.5% 6
2.0 95±5.9% 6
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TABLE 31.
The recovery of temazepam from spiked post-mortem 
blood extracted through a Cg-column and analysed by
HPLC.
Concentration
Ug/ml
Recovery Number of samples
0.05 88±3.5% 6
0.2 98±3.0% 6
0.9 89±3.0% 6
2.0 92±3.0% 6
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TABLE 32.
The recovery of desmethyldiazepam from spiked post­
mortem blood extracted through a Cg-column and
analysed by HPLC
Concentration
|ig/ml
Recovery Number of samples
0.05 86±2.0% 6
0.2 100±2.0% 6
0.9 91±4.0% 6
2.0 92±3.0% 6
TABLE 33
The recovery of diazepam from spiked post-mortem blood 
extracted through a C8-column and analysed by HPLC.
Concentratio 
n |ig/ml
Recovery Number of samples
0.05 93±4.0% 6
0.2 99±3.0% 6
0.9 94±5.0% 6
2.0 92±4.0% 6
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TABLE 34.
Relation between triazolam concentration and the average 
peak height ratio (std/LS) of postmortem blood spiked
with
triazolam extracted through a Cg column and analysed by
HPLC
Concentration
Ug/ml
Mean peak height ratio 
n = 6
0.050 0 .075
0.200 0.23
0.900 1.13
2.000 2.79
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TABLE 35.
Relation between temazepam concentration and the
average
peak height ratio (std/I.S) of postmorte mblood spiked
with
temazepam extracted through a C8 column and analysed
by HPLC.
Concentration
H'g/ml
Mean peak height ratio 
n = 6
0.050 0.047
0.200 0.185
0.900 0.93
2.000 2.03
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TABLE 36.
Relation between desmethyldiazepam concentration and
the average
peak height ratio (std/LS) of postmortem blood spiked
with
desmethyldiazepam extracted through a C8 column and
analysed by HPLC.
Concentration
jig/ml
Mean peak height ratio 
n = 6
0.050 0.0686
0.200 0.30
0.900 1.5
2.000 2.96
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TABLE 37.
Relation between diazepam concentration and the average 
peak height ratio (std/LS) of postmortem blood spiked
with
diazepam extracted through a C8 column and analysed by
HPLC
Concentration
jig/ml
Mean peak height ratio 
n = 6
0.050 0.059
0.200 0.24
0.900 1.20
2.000 2.47
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Figure 25 Separation Of Benzodiazepine Drugs From Spikedwhole 
Post-mortem Blood (50ng)By HPLC System.
1-Triazolam. 2-Temazepam. 3-Desmethyldiazepam.
4-Diazepam. 5-Prazepam.
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TABLE 38 Reproducibility of recovery of benzodiazepine drugs 
over a 3 day period using Cg columns for extraction.
Drug * Days Average
Recoveries
Coefficient
Variation
No.of Samples 
Extracted
1 88% 4.6% 10
Triazolam 2 87% 5.0% 10
3 88% 4.0% 10
1 89% 3.6% 10
Temazepam 2 89% 2.8% 10
3 89% 4.0% 10
Desmethyldiaz 1 90% 5.1% 10
epam 2 91% 3.4% 10
3 91% 4.2% 10
1 94% 4.8% 10
Diazepam 2 94% 3.7% 10
3 94% 3.4% 10
*Drug concentration 0.9ug/ml.
Table 39 Retention Times Of Benzodiazepine Drugs
Analysed By HPLC.
D rug Retention Times 
(minutes)
Triazolam 5.8
Temazepam 6.8
Desm ethyldiazepam 7.9
Diazepam 8.8
Prazepam 13.8
Column: Hypersil 5(im C18 Universal Cartridge (25cmx4.6 i.d).
Mobile phase: 0.01M Di-sodium hydrogen orthophosphate(PH 8.8):methanol (30:70) 
Detection Wavelength: 230 run.
Flow rate: lml/minute.
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IX. Applications of the Developed Method to Authentic Blood Samples 
And a Comparison of the Concentration of Benzodiazepine Drugs 
from Four Different Sites.
Introduction
Having established that levels of benzodiazepine drugs in post­
mortem human blood can be detected at concentrations as low as 50 ng/m l 
following extraction on a Cg column, of 3ml capacity, the developed
method applied to twenty-four human post-mortem blood samples from 6 
cases. The aim was to compare the concentration of the benzodiazepine 
drugs from four different sites (jugular vein, axillary vein, femoral vein 
and the heart). Post-mortem blood samples were collected from the 
fatalities. The characteristics of these cases with respect to age and binding 
site concentration in which triazolam, temazepam, desmethyldiazepam or 
diazepam were detected are summarised in Table 28.
Samples (1 ml whole human post-mortem blood) were extracted 
using non-polar interaction columns (Bond ElutR Cg, 3 ml capacity) for the
analysis of the benzodiazepine drugs (5.2.2.3). Spiked whole human post­
mortem blood and blank (whole post-mortem blood) were extracted in 
parallel each time, and an internal standard was used as before for 
purposes of quantification. Each extraction was performed in duplicate. 
A single point calibration was used since the linearity of the procedure has 
been established above (pp 161-166).
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Instrumental Conditions
The extraction procedure was carried out as described in 5.2.2.3.A-IV. 
The residue was reconstituted in 100 ul of the mobile phase and 20 ul were 
injected into HPLC system. HPLC conditions and the mobile phase were as 
described in 5.12 and 5.13. Detection by UV monitoring at wavelength of 230 
nm.
Results and Discussion
The chromatograms produced from extracts of spiked whole human 
post-mortem blood sample were good. Examples for extracts of spiked whole 
human post-mortem blood, blank autopsy and authentic human autopsy 
blood samples are shown in Figures 26-28.
Table 40 lists the average concentrations of benzodiazepine drugs 
investigated in twenty-four post-mortem human blood samples. This study 
shows that there is a good correlation between the benzodiazepine drugs 
concentration taken from the heart and that taken from the other sites.
Conclusion
It can be concluded from the above results that the concentrations of 
benzodiazepine drugs in the heart, jugular vein, axillary vein and femoral vein 
are comparable. No significant differences could be detected.
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3
Retention Time ( Minutes)
Figure 26 The chromatogram of the four benzodiazepine analysed be HPLC system. 
1. Triazolam 2. Temazepam 3.Desmethydiazepam
4. Diazepam 5.Prazepam( Internal standard)
-172-
5
Retention Time(minutes)
Figure 27 The chromatogram of negative (Blank)human post-mortem 
blood analysed by HPLC system.
1. Traizolam 2. Temazepam 3. Desmethyldiazepam
4. Diazepam 5. Internal standard (Prazepam)
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Figure 28 The Chromatogram Of Authentic Human Post-mortem 
blood Sample Analysed By HPLC System.
1-Temazepam 2-Desmethyl diazepam
2-Diazepam 4-Prazepam(intemal standard)
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Table 40 Average Recoveries Of Benzodiazepine Drugs From 
human Post-mortem Blood Samples From Different 
Sites Using Solid Phase Extraction.
Blood Site Triazolam Temazepam Desmethyl
diazepam
Diazepam
Jugular vein
1 - 0.12 0.33 0.65
2 - 0.32 0.11 0.87
3 - 0.13 - 0.57
4 - 2.54 - -
5 0.45 - 0.80 0.24
6 0.31 - 0.43 0.23
Axillary vein
- 0.12 0.32 0.64
- 0.31 0.11 0.87
- 0.12 - 0.56
- 2.53 - -
0.45 - 0.80 0.24
0.33 • 0.41 0.22
Heart
- 0.12 0.33 0.64
- 0.30 0.10 0.86
- 0.12 - 0.56
- 2.53 - -
0.45 - 0.78 0.22
0.33 - 0.42 0.22
Femoral vein
- 0.12 0.33 0.64
- 0.32 0.11 0.87
- 0.13 - 0.56
- 2.55 - -
0.44 - 0.80 0.24
0.32 • 0.41 0.23
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X. Comparison of Extraction Efficiency of the Developed (Solid-Phase 
Extraction) Method with Liquid-liquid Extraction
Human Post-Mortem Blood Samples
Twenty-four post-mortem blood samples were extracted by a 
conventional solvent extraction method (Eppel, 1980) in parallel with the 
developed non-polar solid-phase extraction procedure.
Liquid-Liquid Extraction
1. Extraction Buffer Preparation
Disodium hydrogen phosphate dihydrate (M.wt. 177.99) buffer was 
made up by dissolving 1.78 grams of Na2HP04 in deionised water and making
up to one litre, producing a buffer concentration of 0.01M with a pH of 7.4.
2. Standard Solution Preparation
A standard solution of benzodiazepine drugs (triazolam, temazepam, 
desmethyldiazepam, diazepam) was made up as before (5.2.2.2.II)
3. Extraction Procedure
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Samples (1 ml whole human post-mortem blood) were extracted using 
liquid-liquid extraction (Eppel, 1980) for analysis for benzodiazepine drugs. 
Spiked and blank whole post-mortem blood were extracted in duplicate each 
time.
0.1 ml of the internal standard solution (prazepam 20 ug/ml) and 1 ml 
of the phosphate buffer (0.01M, pH 7.4) were transferred into a ground-glass 
stoppered test tube. 1 ml of sample and blank blood were added to the tube. 
In the case of standards, 0.9 ml of blank blood followed by 0.1 ml of standard 
benzodiazepine mixture (20 ug/ml) were added then the solutions were 
extracted using 5 ml of dichloromethane in ground glass stoppered test tubes 
placed on a (rock and roll) machine for twenty minutes. The supernatant layer 
was removed by Pasteur pipette. The dichloromethane was filtered through 
phase separation paper into a screw-capped glass vial. The dichloromethane 
was evaporated to dryness at 60°C under a nitrogen gas stream. The extracts 
were redissolved by adding 100 ul of mobile phase and 20 ul was injected 
onto the HPLC.
4. Instrumental Conditions
Both extraction procedures (liquid-liquid extraction and solid-phase) 
were carried out as described in 5.2.2.3. HPLC conditions and the mobile 
phase were as described in 5.1.2.
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5. Results and Discussion
The results of the comparison are given in Table 41. The Cg column
extractions were more efficient than the liquid-liquid extraction. Solid-Phase 
extraction, had the advantage of being extremely clean compared to the 
conventional solvent extraction method.
The developed method has a number of advantages over conventional 
liquid-liquid extraction. The use of bonded silica phase and a solvent 
eliminates emulsion formation between the two immiscible solvents, common 
in liquid-liquid extraction, which results in loss of analyte. The large volume 
of organic solvent utilised by liquid-liquid extraction is often hundreds of 
millilitres compared to the few millilitres used in solid-phase, single-step 
extraction compared to the multiple back extractions often required by liquid- 
liquid extraction. The ability of solid phase extraction to allow separation of a 
drug and its metabolites which cannot often be achieved successfully by 
liquid-liquid extraction, successful automation. Hence solid-phase extraction 
is more efficient than liquid-liquid extraction, in terms of increased amount of 
analyte extracted from the endogenous material and reduced analysis time 
and cost.
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Table 41 Comparison of solid-phase and liquid-liquid extraction of 
benzodiazepines from human blood samples.
No. Triazolam
(u g /m l)
Temazepam
(u g /m l)
Diazepam
(u g /m l)
Desmethyl­
diazepam
(u g /m l)
Extraction Solid Liquid Solid Liquid Solid Liquid Solid Liquid
1 - - 0 . 1 2 0 . 0 9 0 . 6 4 0 . 6 0 0 . 3 3 0 . 2 8
2 - - 2 . 5 4 2 . 3 1 - - - -
3 0 . 4 5 0 . 4 1 - - 0 . 2 2 0 . 1 7 0 . 7 8 0 . 6 8
4 - - 0 . 3 2 0 . 2 3 0 . 8 6 0 . 7 6 0 . 1 0 0 . 0 9
5 - - 0 . 1 2 0 . 0 8 0 . 5 6 0 . 4 2 - -
6 0 . 3 3 0 . 2 6 - - 0 . 2 2 0 . 1 8 0 . 4 2 0 . 3 6
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B. HUMAN BRAIN TISSUE EXTRACTION
I. Introduction
The distribution of benzodiazepine receptors have been investigated in 
post-mortem human brain tissue (4.6) using the binding method described in 
4.5.5. Results indicate a high density in the cortex of the precentral area 
(frontal lobe cortex).
II. Human Brain Tissue
Human post-mortem brain tissue sample was obtained at autopsy from 
a male aged twenty-one years, who died from hanging and had no treatment 
with any benzodiazepine drug at the time of death. In confirmation of the 
above information, a blood sample was taken from the deceased and analysed 
for the presence of benzodiazepines using radio-immunoassay and HPLC and 
was found to be negative by both methods.
The brain was removed at the time of the autopsy (as described in 4.5.3) 
and the grey matter (from precentral area) was freshly dissected without 
thawing and pulverized on dry ice. Dissected tissue (grey matter from the 
precentral cortical area) was stored at -20°C until used.
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III. Extraction Buffer Preparation
0.01M (pH10.4) disodium hydrogen orthophosphate dihydrate 
(Na2HP04.2H20, M.wt 177.99) and 2% ammonia solution (NH3 35%) were
prepared as described in 5.2.2.1.
IV. Standard And Internal Standard Solutions
A stock standard solution 20 ug/ml containing the four benzodiazepine 
drugs (triazolam, temazepam, desmethyldiazepam and diazepam) and the 
internal standard (prazepam 20 ug/ml) were prepared in water as described 
in 5.2.2.2.II. These stock solutions were diluted with deionised water to yield 
concentrations of 1, 2,9  and 2 ug/ml.
V. Sample Preparation
One gram of pulverised control human brain tissue (from the precentral 
cortex area) was transferred to 15 ml screw-capped vial. The following 
solutions were added:
1. - 0.1 ml benzodiazepine drugs standard mixture 20 ug/ml (triazolam,
temazepam, desmethyldiazepam and diazepam).
2. - 0.1 ml internal standard (prazepam 20 ug/ml).
3. - 2.9 ml of 0.01 M Na2HP04 (pH10.4).
4. -1.9 ml of 2% ammonia solution (35% NH3).
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5. 1 mg of subtilisin Carlsberg (crystalline bacterial alkaline protease).
Then the tube was placed in a water bath for 30 minutes at 50-60°C 
with continuous magnetic stirring (to liberate benzodiazepine drugs from the 
tissue). The resulting solution was cooled to room temperature and the tube 
was centrifuged for 10 minutes at 5.000 rpm using a Beckman (J2-21) single 
head centrifuge.
The supernatant was transferred, using a Pasteur pipette, into a 6 ml 
screw capped glass vial.
VI Column Conditioning
Bond ElutR Cg column with a capacity of 6 ml were positioned in a Vac-
Elut system. Vacuum pressure generated by the water pump was kept 
between 50-10 mmHg and the cartridge was not allowed to dry out. The 
cartridges were conditioned by successive application of the following 
solutions:
2 x 4 ml HPLC grade methanol
followed by deionised water 2x4  ml. 
followed by 2 x 4 ml 0.01M Na2HP04(pH 10.4)
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VII. Addition Of Sample
The supernatant (V. above) was transferred to a preconditioned Bond 
ElutR Cg column, 6 ml capacity and drawn through under vacuum pressure.
The column was washed with two millilitres of 0.01M disodium hydrogen 
orthophosphate buffer (pH10.4) followed by five millilitres of hexane.
VIII. Elution Of The Sample
The drug mixture was then eluted with 6 x 1 ml chloroform.
IX. Analysis Of The Sample
The eluate was evaporated under a gentle nitrogen stream on a hot 
plate at 60°C, then the residue was redissolved in 100 ul of the mobile phase. 
Twenty microlitres were injected onto the HPLC system.
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X. Results and Discussion
Recoveries Of The Four Benzodiazepines
A set of spiked human brain tissue samples containing the four 
benzodiazepine drugs mixture were prepared in blank human brain tissue to 
produce the following concentrations of 0.1, 0.2, 0.9 and 2 ug/gram of human 
brain frontal cortex. Internal standard (prazepam) was added to the above 
samples to produce a concentration of 2 ug/gram brain tissue.
Six samples of each concentration set were extracted through Bond 
ElutR Cg column, 6 ml calculated by comparing the peak height ratio of the
extracted sample with un-extracted standard prepared in mobile phase at the 
same concentration.
The chromatograms produced from the human brain tissue (frontal 
cortex) were good. An example is shown in Figure 33.
Tables 42-45 list the concentrations, average recoveries and number of 
samples used each time. Excellent recoveries were obtained for the four 
benzodiazepine drugs.
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TABLE 42.
The recovery of triazolam from spiked human brain tissue 
extracted through Cg column-column and analysed by
HPLC.
Concentration Recovery Number of samples
0.1 101±2.9% 6
0.2 83±5.0% 6
0.9 97± 6.2% 6
2.0 92±7.2% 6
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TABLE 43.
The recovery of temazepam from spiked human brain 
tissue extracted through Cg-column and analysed by
HPLC.
Concentration
l^g/g
Recovery Number of samples
0.1 84±7.0% 6
0.2 100±4.7% 6
0.9 96±3.3% 6
2.0 100±7.0% 6
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TABLE 44.
The recovery of desmethyldiazepam from spiked human 
brain tissue extracted through Cg-column and analysed by
HPLC.
Concentration
^g/g
Recovery Number of samples
0.1 95±8.2% 6
0.2 104±6.2% 6
0.9 101±2.2% 6
2.0 99±7.3% 6
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TABLE 45.
The recovery of diazepam from spiked human brain 
tissue extracted through Cg-column and analysed by
HPLC.
Concentration
ngte
Recovery Number of samples
0.1 95±7.5% 6
0.2 97±3.6% 6
0.9 98±1.4% 6
2.0 99±7.1%
«
6
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Calibration Curves (Linearity)
The previous experiments were used to find optimum conditions for the 
extraction and separation of the drugs. To enable the developed procedure to 
be used for quantitation, it was necessary to demonstrate a linear response for 
the procedure to enable quantitative analysis for each drug from low (0.1 
ug/gram), sub-therapeutic (0.2 ug/gram), therapeutic (0.9 ug/gram) and the 
level expected from fatal ingestion (2 ug/gram).
Standard mixtures were prepared with concentrations ranging from
0.01 ug to 2 ug/gram to find the detection limit for each drug and the 
cleanness of human brain extracts using a solid phase extraction, Cg Bond
ElutR column. The above concentration ranges included the subtherapeutic, 
therapeutic, toxic and fatal levels.
Six samples of each concentration set were extracted and analysed by 
the HPLC system. The peak height ratio against the concentration was plotted 
to construct a calibration curve for each drug over the concentration range of 
0.1-2 ug/gram of human brain tissue (frontal cortex area).
The relationships between the concentration of benzodiazepine drug 
concentrations (triazolam, temazepam, desmethyldiazepam and diazepam) 
and the average peak height ratios (std./I.S) of samples analysed by HPLC are 
illustrated in Tables 46-49. The standard curves were constructed for each 
drug using the peak height ratios (std.I.S), and the benzodiazepine drugs 
concentrations. A linear relation was obtained for each drug as expressed in 
Figure 29-32.
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TABLE 46.
Relation between triazolam concentration in human brain 
and average peak height ratio (std/LS.) following 
extraction through a Cg-column and analysis by HPLC.
Concentration
l^g/g
Mean peak height ratio 
n= 6
0.100 0.130
0.200 0.240
0.900 1.126
2.000 2.420
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TABLE 47.
Relation between temazepam concentration in human 
brain and average peak height ratio (std/LS.) following 
extraction through a C8-column and analysis by HPLC.
Concentration
VS/6
Mean peak height ratio 
n= 6
0.100 0.11
0.200 0.19
0.900 0.99
2.000 2.08
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TABLE 48.
Relation between desmethydiazepam concentration in 
human brain and average peak height ratio (std/I.S.) 
following extraction through a Cg-column and analysis by
HPLC.
Concentration
Mg/ml
Mean peak height ratio 
n= 6
0.100 0.17
0.200 0.314
0.900 1.45
2.000 3.2
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TABLE 49.
Relation between diazepam concentration in human brain 
and average peak height ratio (std/LS.) following 
extraction through a Cg-column and analysis by HPLC.
Concentration
^g/g
Mean peak height ratio 
n = 6
0.100 0.137
0.200 0.27
0.900 1.16
2.000 2.63
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Figure 29 Calibration Curve For Triazolam.
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Figure 30 Calibration Curve For Temazepam.
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Figure 31 Calibration Curve For Desmethyldiazepam.
Correlation Coefficent .999
1 2 
Concentration ug/ml
Figure 32 Calibration Curve For Diazepam
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The Reproducibility Of The Extraction Method
Twenty-four samples of human post-mortem brain tissue spiked with
the four benzodiazepine drugs mixture (triazolam, temazepam,
desmethyldiazepam and diazepam) at a concentration of 0.2 ug/gram of 
human brain tissue were extracted through a Bond ElutR Cg six millilitres
capacity column and analysed by an HPLC system over three successive days.
The ratio of the peak height of each drug over the peak height of 
internal standard prazepam was used to calculated the within day and day-to- 
day variations of the extraction and analysis method of the four
benzodiazepines in human brain tissue (precentral cortex).
Table 50 outlines the average recoveries, coefficients of variation and 
numbers of samples used each time. Excellent recoveries were obtained for 
benzodiazepine drugs samples.
Conclusion
The developed method for extraction of benzodiazepine drugs
(triazolam, temazepam, desmethyldiazepam and diazepam) from brain tissue
offered a very good sensitivity with a very stable baseline and very little 
interference. The reproducibility, recoveries and calibration curves were 
excellent. The chromatographic run time was less than 14 minutes at a flow 
rate of 1 ml/minute and no peaks eluted after the internal standard.
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Figure 50 Reproducibility Of Analysis based on SPE with a C-8 
Column For Benzodiazepine Drugs Over Three Days At 
Concentration Of 0.2|ig\ml.
Drug Days Average
Recoveries
Coeffcient
Variation
NO.Of
Samples
Extracted
1 84.2% 2.5% 8
Triazolam 2 84.0% 3.7% 8
3 85.0% 2.0% 8
1 100% 4.2% 8
Temazepam 2 99.5% 6.1% 8
3 100% 4.1% 8
1 103% 2.2% 8
Desmethyediaz 2 102% 3.6% 8
epam 3 103% 2.9% 8
1 97.1% 5.0% 8
Diazepam 2 98.0% 3.8% 8
3 97.5% 4.7% 8
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XI Application and Comparison of Benzodiazepine Drug Recoveries
from Human Post-Mortem Blood Samples and Human Brain Tissue
Samples using Solid-Phase Extraction
Introduction
Brain tissue may not be routinely analysed in the toxicology laboratory, 
however it is of interest because of the high concentration of benzodiazepine 
receptors localized in the cortex, primarily in the pre-central cortex.
Since most of the benzodiazepine receptors are located in the brain and 
it is the site where most, if not all, of the effects of the drug originate, it is of 
interest to determine the concentration of benzodiazepine drugs in the pre­
central area and relate it to the blood concentration.
Having established that levels of benzodiazepine drugs in post-mortem 
human brain tissue as low as 100 ng/gram, can be detected, the developed 
method was applied to six human post-mortem brain tissue samples. They 
were obtained from fatalities in which benzodiazepine drugs (triazolam, 
temazepam, desmethyldiazepam and diazepam) had been detected in their 
blood samples.
Method
Samples (1 gram of post-mortem human brain tissue) were extracted 
using non-polar interaction columns (Bond E lut^g, 6 ml) for analysis for
benzodiazepine drugs (5.2.2.3.b). Spiked human post-mortem brain tissue and
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blank post-mortem brain tissue were extracted in parallel, and an internal 
standard (prazepam 2 ug/gram) was used for purposes of quantification. 
Each extraction was performed in duplicate and the average is given.
The extraction procedures were carried out as described in 5.2.2.3 for 
both blood and human post-mortem brain tissue samples. Extractions were 
performed in duplicate.
Results and Discussion
The main objective of this research was to determine the 
benzodiazepine receptor site concentrations in post-mortem human brain 
tissue samples from subjects known to have taken benzodiazepine drugs prior 
to death. The results were compared to a control group and a marked drop in 
benzodiazepine receptor site concentrations was observed in the presence of 
the benzodiazepine drug at death as shown in Table 28.
This is confirmed by further evidence using the developed methods of 
solid-phase extraction followed by HPLC on human brain tissue and human 
post-mortem blood samples of the same subjects.
Benzodiazepine drugs were measured in both brain and blood samples. 
The results are presented in Table 51 and the chromatograms produced for 
spiked, blank and human post-mortem brain tissue samples are given in 
Figures 33-35.
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Conclusions
Detection of benzodiazepine drugs in human brain tissue by using the 
developed analytical techniques (binding study and solid-phase extract HPLC) 
provide unquestionable evidence of their use. These methods can be used for 
routine screening and subsequent confirmation of benzodiazepine drugs in 
blood and human brain tissue samples.
It has now become possible to study the receptor occupancy in the 
human brain tissue, which is the critical determinant for biological response. 
This will help to determine to what extent blood level measurements are a 
predictor for receptor occupancy in the brain tissue.
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i
InjectionRetention Time( minutes)
Figure 33 Separation Of Benzodiazepine Drugs By HPLC System^ 
1-Triazolam 2-Temazepam 3-Desmethyldiazepam
4-Diazepam 5-Prazepam(Internal standard)
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Retention Time( minutes)
Injectior
Figure 34 The Chromatogram Of Negative(Blank)Human Post-mortem 
Brain Tissue Analysed By HPLC System.
1-Triazolam 2-Temazepam 3-Desmethyldiazepam
4-Diazepam 5-Prazepam(Intemal standard)
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i
TT
Injection15
Retention Time( minutes)
Figure 35 The Chromatogram Of Authentic Human Post-mortem 
Brain Tissue Sample Analysed By HPLC System.
1-Temazepam 2-Prazepam(intemal standard)
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Table 51 Analysis Of Benzodiazepine Drugs In Human Post- 
Mortem Blood and Human Brain Tissue Samples Using Solid-
phase Extraction.
No. Triazolam Temazepam Diazepam Desmethyldia
zepam
Extraction Blood
(ug/ml
Brain
(ug/g)
Blood
(ug/ml
Brain
(ug/g)
Blood
(ug/ml
Brain
(ug/g)
Blood
(ug/ml
Brain
(ug/g)
1 - - 0.12 0.08 0.64 0.57 0.33 0.25
2 - - 2.54 2.20 - - - -
3 0.45 0.35 - - 0.22 0.12 0.78 0.66
4 - - 0.32 0.21 0.86 0.71 0.10 0.07
5 - - 0.12 0.06 0.56 0.44 - -
6 0.33 0.23 - - 0.22 0.14 0.42 0.32
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6. CONCLUSIONS
Benzodiazepine drugs are the most frequently encountered drugs in 
toxicological investigations in the U.K. after paracetamol (acetaminophen). 
These drugs have been prescribed for over 20 years, primarily as tranquillisers 
and anti-anxiety agents. Additionally, they have been used as both muscle 
relaxants and anticonvulsant agents. Temazepam has become one of the most 
common drugs by injection among drug abusers.
They evoke their pharmacological effects by binding to specific sites in 
brain tissue (receptors).
Little has been published on the routine screening and subsequent 
confirmatory analysis of the drugs in whole human post-mortem blood and 
brain tissue samples. Possibly this is as a result of problems, including co­
extracted lipid and other materials which can give rise to interferences. 
Therefore, it can be seen that recovery of benzodiazepine drugs from post­
mortem materials presents a challenging problem for the toxicologist.
Highly modem, sophisticated analytical and instrumental techniques 
such as binding studies and solid-phase extraction have been used in this 
research to overcome the problems of co-extracted materials. These techniques 
provide a quick clean-up procedure, give both high drug recoveries and 
complete removal of interfering materials, and decreased sample preparation 
time.
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A. Binding Studies
From binding study techniques several conclusions are apparent. The 
first of these obtained from the saturation curve, is that the optimal incubation 
time for benzodiazepine receptors and 3-flunitrazepam is between 30 minutes 
minimum and 60 minutes maximum. Secondly, the highest densities of 
binding sites were found to be in the frontal lobe cortex (grey matter) area. 
Intermediate densities were found in other areas (post-central cortex, occipital 
cortex and hippocampus). The lowest densities were observed in the 
cerebellum and temporal cortex.
Finally a considerable drop in the receptor binding site concentrations 
was noted in subjects known to have taken benzodiazepine drugs prior to 
death as compared to the control group. The drug presence was confirmed by 
High Liquid Chromatography. Variations in the cortical synaptosomal 
binding site concentrations were shown to be slightly affected by age and sex 
factors.
- 2 0 8 -
B. Solid-Phase Extraction of Benzodiazepine Drugs from Post-mortem
Blood and Human Brain Tissue Samples,
1. Human Post-Mortem Blood
A highly efficient and sensitive solid phase-extraction method for the 
dilution and measurement of benzodiazepine drugs in whole human post­
mortem blood samples was developed. The method compared well with 
conventional solvent extraction being more efficient and allowing ready 
identification and quantitation of the benzodiazepine drugs studied The 
developed procedure has advantages of minimal handling time, high recovery 
(even at subtherapeutic levels) clean sample extracts and eliminates the need 
for expensive equipment such as centrifuges, shakers and glassware.
Blood was also analysed from four different anatomical sites (jugular 
vein, axillary vein, femoral vein and the heart) and the concentrations of 
benzodiazepine drugs at each site were measured by HPLC. No significant 
variations in the drug concentrations were found between these sites.
2. Human Brain Tissue
As shown there is a major diminution in the number of benzodiazepine 
receptors measured is the presence of benzodiazepine drugs at death. In order 
to confirm this finding a solid phase extraction procedure for benzodiazepine 
drugs in human brain tissue (frontal lobe cortex) samples was developed and 
applied to the same subjects. This method proved to be highly efficient and 
sensitive. The method was used to confirm the presence of the drugs in the
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brain tissues where saturation curve analysis had shown a drop in the number 
of benzodiazepine receptors.
Finally, a comparison study was made between the concentrations of 
benzodiazepine drugs extracted from human brain tissue and human post­
mortem blood samples. It was observed that drugs were present in both 
samples from the same subjects. Higher benzodiazepine concentrations were 
obtained from blood compared to brain samples.
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THE EFFECT OF BENZODIAZEPINE DRUGS ON THE BINDING SITE 
CONCENTRATION OF BENZODIAZEPINE RECEPTORS
Oliver, J.S. and Azab, M.
Department of Forensic Medicine and Science, University of Glasgow, 
Glasgow, Scotland, U.K.
The toxicological investigation of death by poisoning relies primarily on 
the analysis of a biological sample for the presence of the suspected drug. As a 
result, a level can be measured which can be compared with findings from 
previous cases. The finding will lie within the "fatal", "toxic", "therapeutic", or 
"sub-therapeutic" range. Increased sophistication on this interpretation has 
been reported at previous T.I.A.F.T. conferences where reported use has been 
made of the comparison of drug levels measured in samples taken from 
different sites in the body. This study presents the results of a preliminary 
investigation of the potential use of drug receptors as a means of diagnosing 
death by poisoning.
After paracetamol (acetaminophen), benzodiazepine drugs are the most 
frequently encountered in toxicological investigations in the West of Scotland. 
These drugs have been prescribed for over 20 years, primarily as tranquillisers 
and anti-anxiety agents. Additionally, they have been used as both muscle 
relaxants and anticonvulsant agents(l,2,3). One of them, Temazepam, has, by 
injection become one of the most commonly encountered drugs with drug 
abusers.
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They evoke their pharmacological effects by binding to specific sites in 
brain tissue, receptors (4-10).
Following optimisation of the method, the regional distribution of 
benzo-diazepine receptor sites in the brain was investigated. As a result, the 
site with the highest population of receptors was studied to determine the 
possible effect on the receptor population of age, sex cause of death and time 
interval between death and autopsy. The results were compared with the 
apparent binding site concentration measured in subjects shown to be on 
benzodiazepine drugs at death.
MATERIALS AND METHOD
Clonazepam was obtained from Wyeth Laboratories. The tritiated 
flunitrazepam ([3H]FNZ), specific activity 85 Ci/mmol was purchased from 
Amersham International pic. All other chemicals were of analytical quality 
and were obtained from local suppliers.
Human post mortem tissue samples were collected at the City 
Mortuary, packed in ice, and transported to the laboratory for immediate 
processing. For all cases, blood samples were analysed by high pressure liquid 
chromatography and by radioimmunoassay for the presence of 
benzodiazepine drugs.
Benzodiazepine receptors were harvested by homogenising 
approximately 1 gramme of brain tissue in 10 millilitres of ice-cold 0.32mol 
sucrose solution using 20 strokes of a teflon-glass homogeniser at 1200 rpm.
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The homogenate was centrifuged at 3500 rpm for 10 minutes at 4°C. The 
supernatant was removed and was further centrifuged at 15,000 rpm for 20 
minutes at 4°C. The pellet formed was weighed, resuspended in 10 millilitres 
of 25mmol sodium phosphate buffer (pH 7.4) and stored at -20°C until 
analysed.
On the day of the investigation, homogenates were thawed. The protein 
concentration of the preparation was measured by the colourimetric method of 
Lowrey et al (11) whereby the protein-copper-Folin reagent complex can be 
measured in a spectrometer at a wavelength of 540nm.
The binding site concentration was measured using a modification of 
the method described by Horton et al (12,13). The protein concentration of the 
homogenate was adjusted by dilution to between 0.1 and 0.3mg per millilitre.
In duplicate, aliquots of homogenate (0.8ml) were mixed thoroughly
with six serial dilutions of [3H]FNZ ( 0.1ml of 0.3 - 0.009nmol/ml). For total
binding, 0.1ml of assay buffer (25mmol sodium dihydrogen phosphate pH7.4)
was added, for non-specific binding, the later was replaced with 0.1ml of
Clonazepam (2umol/ml in assay buffer). Each tube was mixed well and
incubated for 60 minutes at room temperature (20°C). The bound and free
fractions were separated by filtration under low vacuum through Whatman
GF/B glass fibre filters. The filters were rinsed under vacuum with 5ml ice- 
cold assay buffer. The filters were then placed into P3 Pico vials (Packard),
4ml of scintillant fluid (Ecosdnt, National Diagnostics) was added and the 
vials were shaken vigorously. The bound radiolabel was measured by liquid 
scintillation counting for one minute (Packard 2200 CA).
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The DPM of total added label was determined by addition of 0.1ml of 
each radioligand concentration directly to 4ml of sdntillant fluid which was 
counted for 1 minute.
All data was processed using the Packard Combicept Program.
RESULTS AND DISCUSSION
1. Effect of Incubation Period
Human post-mortem brain tissue samples were obtained at autopsy 
from a female aged 18 years, who died from chest and abdominal 
injuries(RTA). A blood sample was taken from the deceased and analysed for 
the presence of benzodiazepines using radioimmunoassay and HPLC with 
negative results. The grey matter from the frontal cortex area was freshly 
dissected taking care to avoid contamination by white matter.
In order to determine a suitable period of the receptor/ligand 
equilibrium, 24 LP3 tubes were set up in pairs, enabling duplicates to be 
filtered at (0,30,60,120 and 150 minutes). Binding site concentration was 
determined as above.
The results are shown in Table 1. From the chosen time intervals, it can 
be seen that an incubation of between 30 and 60 minutes is sufficient to allow 
an equilibrium to be achieved between the receptors and the radioligand. At 
120 and 150 minutes, there is clear evidence of breakdown of the receptor-
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radioligand bond, perhaps due to denaturation or proteolysis of the receptor 
protein. A period of 60 minutes was selected for the remaining experiments.
2. Regional distribution of benzodiazepine receptors in 
human brain tissue
Brain tissue was obtained at autopsy from four females and two males. 
Analysis for the presence of benzodiazepine drugs in each case gave a negative 
result.
Table 2 shows the regional distribution of benzodiazepine receptors in 
the six areas studied. The highest levels of specific ^H-flunitrazepam binding 
was found in the frontal cortex and the lowest densities were found in the 
temporal cortex. This study agrees with other investigators.
3. Influence of Age, Sex, Causes of Death and Time 
Interval between Death and Autopsy
The benzodiazepine receptor concentration in frontal cortex was 
determined for 36 post-mortem cases which had been found to be negative for 
benzodiazepine drugs.
Table 3 summarizes the characteristics of these cases with respect to age 
and sex. There were variations in binding site concentration between the 
deceased according to age, especially in the male. For the group of age <40 
years, the number of benzodiazepine receptors in the frontal cortex was 
measured as 1305 +/- 92. For group 2 (40-60) and group 3 (>60) a decrease in
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the number of benzodiazepine receptors (1267 +/- 9 and 1166 + /- 57 
respectively) was found.
In females the 3 age groups showed no variations in binding sites in all 
three groups of age.
Tables 4-7 lists the binding site concentrations measured in males and 
females with respect to causes of death and the time interval between death 
and autopsy.
With respect to the delay between time of death and post-mortem, the 
results in the table show no significant effect. This is possibly due to storage of 
the bodies in refrigerator prior to autopsy. Also, the cause of death shows no 
significant change in the binding site concentrations.
4. The Effect of Benzodiazepine Drugs
The apparent receptor binding site concentration in six subjects who 
died from a variety of causes but who were shown to have taken 
benzodiazepine drugs prior to death were measured. The results in table 8 
show a considerable drop in the apparent binding site concentrations when 
compared to the control group.
CONCLUSION
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This study has shown the highest concentration of benzodiazepine drug 
receptors to be found in the Frontal Cortex. A possible diminution of numbers 
is to be found with age. A larger amount of data will have to be collected to 
confirm both this and a possible sex difference. The major diminution in the 
number of benzodiazepine receptors measured is the presence of a 
benzodiazepine drug at death. Further study is required to quantitate this 
difference between the apparent and the true and perhaps as a result increase 
our interpretive powers in cases of drug death.
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Table 1: Effects of incubation time against binding site 
concentration
Time (min) Binding site concentration 
(fmol/mg protein)
Mean
0 800 775
750
30 1253 12453
1238
60 1286 1283
1276
120 1138 1150
1162
150 1067 983.5
900
Table 2: Regional distribution of benzodiazepine receptors 
in human brain tissue  ______________
Brain Maximum specific binding site 
(fmol/me protein)
statis­
tics
Frontal 1341 1216 1325 1362 1126 1300 -1278/4
SD-90.2
cv-7.05%
Pvt-
central
cortex
1030 981 1062 1170 1098 998 -1039.8
SD-6B.89
cv^.50%
Occi­
pital
cortex
1016 1092 927 1060 1090 960 -1024.2
SXM9.QS
cv»d>.74%
Hippo­
campus
841 910 807 980 896 900 -889 
SD-6 
cv—0.7%
Cere­
bellum
662 542 613 590 642 660 -618.2 
SD -46^ 
cv—7.5%
are!
cortex
638 700 590 610 561 531 -605 
SD-59.6 
cv—9.8%
Table 3: Binding site concentration of benzodiazepine receptors 
in the human frontal cortex area against sex and age group.
Binding site concentration (fmol/mg protein)
Age group Case No. Male Female
nl 1328 1281
n2 1375 1305 1250 1268
<40 n3 1270 SD92 1305 SO 307
years n4 1210 cv7% 1220 cvlA'h
n5 1230 1290
n6 1217 1260
nl 1272 1215
n2 1157 1267 1210 1250
40-60 n3 1212 SD90 1320 SD6.1
years n4 1193 cv7% 1185 cv4.9%
n5 1230 1236
n6 1290 1333
nl 1275 1281
n2 1133 1166 1250 1268
>60 n3 1168 SD90 1305 SO 47
years n4 1172 cv43% 1220 cv3.9%
n5 1232 1290
n6 1208 1260
Table 4: Effects of age and cause of death 
on binding site concentration in females
Age Time interval
(death 4c Bstopsy)
Binding site 
Concentration
18 Cheat 4c Abdominal 
inturiea (RTA)
1220
31 Myocarditis 1305
33 Phenobarbltone
intoxication
1260
36 Acute Alcohol 
Intoxication OITA)
1250
37 Spontaneous 
wtbarachnoid haem- 
rrhage due to 
rupture of cerebral 
arterv aneurvsm
1290
38 Acute peritonitis 
due to chronic 
DancreatttU
1281
46 Myocardial
Infarction
1333
47 Scalding due to hot 
water
1215
47 Coronary thrombosis | 1185
48 Aiutr myocardial 
infarction
1236
53 Ischaemic heart 
disease
1320
59 Hypertension & 
Ischaemic heart 
disease
1216
62 Ischaemic heart 
disease
1210
68 Lobar pneumonia 1190
68 Acute myocardial 
Infarction
1330
68
due to myocardial 
infarction
1157
78 Ischaemic heart 
disrate Coronary 
artery atheroma
1212
85 Metattatic large 
bowreL Cardnoma 4c 
pulmonary thrombo- 
embolism
1180
- 2 4 3 -
Table 5: 
autopsy) 
females
Effects of time interval (death & 
on binding site concentration in
Age Time interval
(rl—th 4e  autopsy)
3 | iu 1Jb |  l i t*  
Conamtiteian
46 12 hours 1333
62 12 hours 1210
53 14 hours 1320
68 17 hours 1330
68 19 hours 1190
85 24 hours 1181
31 24 hours 1305
18 34 hours 1220
33 34 hours 1260
38 34 hours 1281
47 52 hours 1185
37 54 hours 1290
78 73 hours 1212
47 74 hours 1215
48 76 hours 1236
59 80 hours 1216
36 86 hours 1250
68 88 hours 1157
Table 7: 
autopsy) 
males
Effects of time interval (death & 
on binding site concentration in
Age Time interval
(death It. autopsy)
Binding site 
Concentration
49 18 hours 1272
68 23 hours 1168 '
19 30 hours 1341
64 36 hours 1263
58 38 hours 1157
48 49 hours 1272
19 72hours 1362
55 72 hours 1325
76 72 hours 1136
38 82 hours 1126
37 84 hours 1300
74 84 hours 1113
75 84 hours 1194
37 86 hours 1375
73 95 hours 1119
37 97 hours 1328
46 102 hours 1223
48 141 hours 1121
Table 6: Effects of age and cause of 
death on binding site concentration in 
eighteen males
Age Time interval
(dcteh <c autopsy)
Binding site 
Concentration
19 Multiple Injuries, 
Roed Traffic 
Acddent
1341
19 Acute alcohol 
Intoxication
1362
37 Acute pancreatitis 1300
37 Coronary artery 
atheroma
1328
37 Cheat it abdominal. 
Road traffic accident
1375
38 Hanging 1126
46 Cerebral sbaceas 1223
48 Hanging 1272
48 Acute artery 
atheroma
1121
49 Acute myocardial 
Infarction
1272
55 Coronary artery 
atheroma^ Bronchttia 
fc emphysema
1325
58 Choking 1157
64 Acute myocardial 
infraction
1263
68 Ischaemic heart 
disease
1168
73 Ruptured aortic 
aneurysm
1119
74 Pulmonary thrombo­
embolism
1113
75 Acute broncho­
pneumonia
1194
76 Haemoperiadlum 
due to myocardial 
Infarction
1136
Table 8: Changes in the density of the benzodiazepine 
receptors in the post-mortem brain samples of six
Age
(years) Sex
Binding Site 
Concentration
(fmol/mg protein)
Blood sample
analysis
(HPLC&RIA)
26 male 833 Temazepam, D.M 
.D. & Diazepam
33 male 772 Temazepam & 
Diazepam
58 female 610 Temazepam
24 male 844 Temazepam, D.M 
.D. & Diazepam
24 male 976 Triazolam, D.M. 
D. & Diazepam
20 female 658 Temazepam, D.M 
.D. & Diazepam
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